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3Abstract
Abstract
Background. Ropivacaine, a long-acting,
enantiomerically pure amide-type local
anesthetic, undergoes extensive hepatic
metabolism in humans, with about 1% of
an intravenous dose excreted unchanged
in the urine. It is metabolized to 3-OH-
ropivacaine by CYP1A2, and to PPX by
CYP3A4.
The aims of the present studies were to
investigate (1) the effects of inhibition
(with fluvoxamine, ciprofloxacin, erythro-
mycin, clarithromycin, itraconazole, and
oral contraceptives) and induction (with
cigarette smoking and rifampicin) of
CYP1A2 and CYP3A4, and (2) the effect
of chronic end-stage liver disease on the
pharmacokinetics of ropivacaine.
Methods. A total of 44 (26 female and
18 male) healthy volunteers participated
in Studies I to V, and 13 (7 female and 6
male) patients with chronic end-stage liv-
er disease in Study V. The first four stud-
ies were placebo-controlled, randomized,
double-blind, and cross-over in design, to
assess the effects of clarithromycin, itra-
conazole, erythromycin, fluvoxamine, and
rifampicin on the pharmacokinetics of
ropivacaine. The effect of oral contracep-
tives was evaluated in the combined pla-
cebo phases of these four studies. Study
III was also designed to compare the phar-
macokinetics of ropivacaine in smokers
and nonsmokers. Study V was an open
parallel group study to assess the effect on
the pharmacokinetics of ropivacaine of
chronic end-stage liver disease. After the
pretreatments with these inhibitors or in-
ducers in Studies I to IV, and without any
pretreatment in Study V, each subject re-
ceived an intravenous infusion of 0.6 mg/
kg ropivacaine hydrochloride during a
period of 30 minutes. Ropivacaine, 3-OH-
ropivacaine, and PPX in venous plasma
and in urine samples were measured for
up to 12 and 24 hours, respectively.
Results. Fluvoxamine reduced the ropi-
vacaine clearance by 77% and ciprofloxa-
cin by 31%. Itraconazole, erythromycin,
and clarithromycin reduced the clearance
only insignificantly, but a combination of
fluvoxamine and erythromycin reduced it
by 86%. Fluvoxamine and ciprofloxacin
raised the excretion of PPX in urine, and
reduced the urinary excretion of 3-OH-
ropivacaine. Itraconazole reduced the ex-
cretion of PPX in urine, and erythromy-
cin raised the urinary excretion of 3-OH-
ropivacaine. Oral contraceptives reduced
the ropivacaine clearance by 49%, elevat-
ed PPX excretion, and reduced the 3-OH-
ropivacaine excretion. Chronic end-stage
liver disease reduced the ropivacaine clear-
ance by 60% and reduced the urinary ex-
cretion of 3-OH-ropivacaine, without af-
fecting the PPX excretion. Fluvoxamine,
combined fluvoxamine and erythromycin,
and chronic end-stage liver disease caused
an increase in the fraction excreted in urine
as unchanged ropivacaine.
Conclusions. The results of the present
studies demonstrate the principal role of
hepatic CYP1A2, and suggest the modest
role of CYP3A4, in the elimination of rop-
ivacaine in humans in vivo. The combina-
tion of fluvoxamine and erythromycin re-
duced ropivacaine clearance by 86%, im-
plying ropivacaine plasma concentrations
about 7-fold higher at steady-state during
continuous ropivacaine infusion. When
continuous infusion or multiple injections
of ropivacaine are given, clinicians should
be aware of increased plasma concentra-
tions in patients taking potent CYP1A2
inhibitors, or a combination of CYP1A2
and CYP3A4 inhibitors, as well as in pa-
tients with chronic end-stage liver disease.
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Abbreviations
3-OH 3-hydroxy
AAG alpha
1
-acid glycoprotein
Ah aryl hydrocarbon
ATP adenosine triphosphate
AUC area under plasma drug concentration-time curve
AUC
0-t
area under plasma drug concentration-time curve up to t hours
cAMP cyclic adenosine monophosphate
CAR constitutive androstane receptor
CL systemic plasma clearance
C
max
peak plasma concentration
CNS central nervous system
CV coefficient of variation
CYP cytochrome P450
DNA deoxyribonucleic acid
ED
50
median effective dose
ED
95
dose producing desired effect in 95% of subjects
E
H
hepatic extraction ratio
f
e
cumulative fraction of dose excreted in urine
f
m,3-OH
fraction of dose metabolized to 3-OH-ropivacaine and excreted in urine
f
m,PPX
fraction of dose metabolized to PPX and excreted in urine
GABA
A
gamma-aminobutyric acid receptor type A
k
el
elimination rate constant
K
i
inhibition constant
K
m
Michaelis-Menten constant
LDL low-density lipoprotein
MI metabolic intermediate
mRNA messenger ribonucleic acid
MRT mean residence time
NMDA N-methyl-D-aspartate
NS not statistically significant
pK
a
negative logarithm of acid ionization constant
PPAR peroxisome proliferator-activated receptor
PPX 2’,6’-pipecoloxylidide
PXR pregnane X receptor
RNA ribonucleic acid
SD standard deviation
t
½
elimination half-life
t
max
time at which highest concentration occurs
V
max
maximum velocity of metabolism
V
ss
steady-state volume of distribution
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Introduction
Regional anesthesia continues to bean attractive choice for anesthesiaand analgesia, due to a renewed
emphasis on perioperative analgesia and
improved local anesthesia techniques,
equipment, and drugs (Wedel 2000). Lo-
cal anesthetics are now often administered
continuously via epidural catheters, but
also by means such as via brachial or lum-
bar plexus catheters (Enneking and Wedel
2000).
Ropivacaine is an amide-type local an-
esthetic with a structure homologous to
that of bupivacaine. It is used for surgical
anesthesia and postoperative pain manage-
ment by epidural administration, periph-
eral nerve blocks, and local infiltration
(McClure 1996). It undergoes mainly ox-
idative hepatic metabolism in humans,
with approximately 1% of an intravenous
dose excreted unchanged in the urine. It
is metabolized to 3-hydroxyropivacaine (3-
OH-ropivacaine) mainly by cytochrome
P450 (CYP) 1A2, and to 2’,6’-pipecolox-
ylidide (PPX) mainly by CYP3A4 (Oda et
al. 1995, Ekstrom and Gunnarsson 1996,
Halldin et al. 1996).
High local anesthetic plasma concen-
trations, for example due to altered phar-
macokinetics, can lead to toxic central
nervous system (CNS) or cardiovascular
symptoms. Even if the risk of toxicity
seems to be less with ropivacaine than with
the older long-acting local anesthetic drug
bupivacaine, high ropivacaine plasma con-
centrations can lead to severe toxic symp-
toms (Ohmura et al. 2001).
CYP-related drug interactions are
known to affect pharmacokinetics of many
drugs. Fluvoxamine and ciprofloxacin are
known inhibitors of CYP1A2 (Fuhr et al.
1992, Rasmussen et al. 1995), and eryth-
romycin, clarithromycin, and itraconazole
inhibit CYP3A4 (Thummel and Wilkin-
son 1998). Rifampicin is a potent inducer
of CYP3A4 and some other CYP enzymes
(Venkatesan 1992, Bertz and Granneman
1997), and cigarette smoking induces
biotransformation of drugs metabolized by
CYP1A2 (Spigset et al. 1995, Zevin and
Benowitz 1999).
The liver is the main organ responsible
for drug metabolism. Ropivacaine has a
relatively low (about 40%) (Arlander et al.
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1998) hepatic extraction ratio (E
H
), so its
total plasma clearance (CL) depends most-
ly on hepatic enzyme activity and plasma
protein binding, and its unbound (intrin-
sic) clearance on only the enzyme activity
(Tucker 1994).
The present studies investigated the ef-
fects of some clinically important CYP1A2
and CYP3A4 inhibitors and inducers, and
the effect of chronic end-stage liver dis-
ease, on the pharmacokinetics of ropiv-
acaine.
11
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Review of the literature
Pharmacokinetics of local
anesthetics
Pharmacokinetics concerns the mathemat-
ical description and prediction of the time-
course of a drug and its metabolites in the
body (Tucker 1994, Rowland and Tozer
1995). The pharmacokinetics of a drug
depends on its absorption and disposition.
Absorption is defined as the process in
which an unchanged drug proceeds from
the site of administration to the site of
measurement (usually plasma), and dispo-
sition as all the processes subsequent to
absorption. Disposition consists of distri-
bution and elimination. Distribution is
defined as the process of reversible trans-
fer of a drug to and from the site of mea-
surement, and elimination as the irrevers-
ible loss (by excretion or metabolism) of
the drug from the site of measurement
(Rowland and Tozer 1995).
Drugs are administered either intravas-
cularly (most usually intravenously) or
extravascularly, e.g., via the oral, intramus-
cular, or rectal route. In intravascular ad-
ministration, the drug enters the blood
directly without absorption. In extravas-
cular administration, the drug is absorbed
from the site of administration into the
blood, to be carried to all organs of the
body, in most cases including those upon
which the drug acts and by which it is elim-
inated (Rowland and Tozer 1995).
Administration can also be divided into
enteral and parenteral, depending on
whether the drug enters the body via the
alimentary tract or via some other route
(Friel 1985).
In clinical use, local anesthetics are ad-
ministered regionally (extravascularly and
parenterally), near the nerves to be desen-
sitized. The duration of a neural blockade
thus depends on the absorption of the lo-
cal anesthetic from the site of administra-
tion (Emanuelsson et al. 1997a, Thomas
and Schug 1999). The systemic toxicity
of local anesthetics, however, is related to
the (free) plasma concentrations of the
drug (Tucker 1986), and thus depends
both on the absorption and the disposi-
tion of the drug (Emanuelsson et al.
1997a).
12
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Absorption
Absorption of local anesthetics is primari-
ly and directly related to local blood flow,
and inversely related to local tissue bind-
ing. Local tissue perfusion depends most-
ly on the site of injection, and decreases in
the order intercostal > epidural > brachial
plexus > sciatic/femoral. The rate of dis-
sociation of local anesthetics from proteins
and adipose tissue at the injection site de-
pends on agent-specific factors like degree
of ionization, lipophilicity, and plasma-
protein binding  (Tucker 1986, Thomas
and Schug 1999).
The rate of absorption of an extravas-
cularly administered local anesthetic dose
is indirectly described by the peak plasma
drug concentration (C
max
) and the time at
which it occurs (t
max
). The extent of ab-
sorption is described by the ratio of the
area under the plasma drug concentration-
time curve (AUC) to the AUC measured
after an identical intravenous dose (Tuck-
er 1986). After a perineural injection, if
no local metabolism occurs, this ratio
should equal one.
The amide-type local anesthetics are all
weak bases and relatively highly lipid sol-
uble. They exhibit a biphasic pattern of
systemic absorption related to absorption
from the aqueous and lipoid structures at
the site of the injection (Thomas and
Schug 1999). Epinephrine retards systemic
uptake of  (some) local anesthetics (at some
sites) by limiting the blood flow at the site
of injection (Tucker 1986).
Disposition
Disposition thus consists of distribution
and elimination. The distribution rate of
local anesthetics is perfusion-limited. Ini-
tially, rapid uptake from plasma by highly
perfused tissues occurs, followed by slow-
er uptake into muscle and fat. At steady
state, distribution is directly proportional
to tissue binding and inversely proportion-
al to plasma- and blood-cell binding.
The main plasma proteins involved in
drug binding are albumin, alpha
1
-acid gly-
coprotein (AAG), and lipoproteins. AAG
is mainly responsible for binding of basic
drugs like local anesthetics. The volume
of distribution at steady state (V
ss
) de-
scribes the extent of tissue distribution
with reference to the plasma (or blood)
drug concentration (Tucker 1986, Thomas
and Schug 1999).
Elimination of a drug from the body
depends on blood flow, blood binding, and
the intrinsic function of the eliminating
organ, usually the liver. Amide-type local
anesthetics are administered parenterally,
and are primarily cleared from plasma by
hepatic metabolism. The hepatic clearance
depends largely on liver blood flow for
drugs with a high (> 70%) hepatic extrac-
tion rate, and on enzyme activity for drugs
with a low (< 30%) extraction rate. The
majority of amides have an intermediate
extraction ratio, and the CL of an un-
bound drug depends on both the hepatic
blood flow and the intrinsic activity of the
hepatic enzymes (Tucker 1986, Thomas
and Schug 1999). CL can be calculated as
CL = dose / AUC (Rowland and Tozer
1995).
Disposition—the combined process of
distribution and elimination—is general-
ly described by the terminal elimination
half-life (t
1/2
), calculated from the elimi-
nation rate constant (k
el
) by t
1/2
 = ln2/k
el
(Rowland and Tozer 1995). If drug elimi-
nation is faster than absorption, however,
for example, after epidural administration
of local anesthetic, k
el
 reflects the absorp-
tion rate rather than the elimination rate.
In these cases, it would be more meaning-
ful to report mean residence time (MRT),
13
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which reflects the average time a drug
molecule remains in the body (Thomas
and Schug 1999). MRT is related to V
ss
and CL as follows: MRT = V
ss
/CL (Row-
land and Tozer 1995).
Plasma protein binding
Plasma free-drug concentration, rather
than total drug concentration, is related
to toxic effects (Tucker 1986). During a
postoperative epidural infusion of ropiv-
acaine, the postoperative increase in plas-
ma AAG levels is associated with a decrease
in the free fraction (f
u
) of ropivacaine and
an increase in total ropivacaine plasma
concentrations, while the unbound ropi-
vacaine concentrations remain stable
(Erichsen et al. 1996).
For two reasons, protein binding has
only a limited effect on the free concen-
trations of  ropivacaine: First, ropivacaine
has a relatively large V
ss
 of 42 L (or about
0.55 L/kg body weight) (Lee et al. 1989),
and under steady-state conditions only a
small percentage of the dose is confined
to the plasma. Second, ropivacaine has a
relatively low E
H
, and pharmacokinetic
theory predicts that the free plasma con-
centration at steady state mainly depends
on the enzyme activity, not on the plas-
ma-protein binding (Tucker 1994, Erich-
sen et al. 1996).
Drug metabolism and CYP
enzymes
Drug metabolism
The major mechanism for elimination of
drugs from the body is metabolism; only
relatively few drugs are eliminated un-
changed by the kidneys (Rowland and
Tozer 1995). The liver is the major organ
for drug biotransformation (Meyer 1996),
but drug-metabolizing enzymes are also
present at other sites, such as the gas-
trointestinal and respiratory tracts, kidney,
lung, brain, and skin. Extrahepatic drug
metabolism is evident, for instance, when
total body clearance exceeds liver blood
flow, or when even severe liver dysfunc-
tion does not affect metabolic clearance
(Krishna and Klotz 1994, Ding and Ka-
minsky 2003).
Most pharmacologically active mole-
cules are lipophilic and, to be excreted,
must be enzymatically biotransformed into
water-soluble metabolites. These metabo-
lites are often less active than the parent
drug, but sometimes biotransformation
may enhance activity or toxic effects. The
most common routes of drug metabolism
are oxidation, reduction, hydrolysis, and
conjugation. A drug can frequently under-
go metabolism by several competing path-
ways, and metabolites may undergo fur-
ther metabolism. Oxidation, reduction,
and hydrolysis often occur first and are
commonly referred to as Phase I (or func-
tionalization) reactions, with conjugations
commonly referred to as Phase II reactions
(Rowland and Tozer 1995, Meyer 1996).
CYP enzymes
Cytochrome P450 was so named, in 1961,
because the pigment (P) has a 450-nm
spectral peak when reduced and bound to
carbon monoxide. Originally CYP was
thought to be a single enzyme, and by the
mid-1960s it was associated with drug and
steroid metabolism. After advances in
messenger ribonucleic acid (mRNA) pu-
rification in the early 1980s, cloning stud-
ies have revealed dozens of different CYP
enzymes (Nebert and Russell 2002), which
comprise a superfamily of heme-thiolate
proteins, and are found in every class of
organism. This superfamily is believed to
have originated from an ancestral gene that
14
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existed over 3 billion years ago. In humans,
CYP enzymes play a central role in Phase
I drug reactions, are involved in many drug
interactions, and contribute to interindi-
vidual variability in drug metabolism
(Guengerich 1992, Danielson 2002). In
addition to participating in drug- and for-
eign-compound metabolism, CYP en-
zymes also play roles in the metabolism of
arachidonic acid and eicosanoids, choles-
terol metabolism and bile-acid biosynthe-
sis, steroid synthesis and metabolism, vi-
tamin D(3) synthesis and metabolism, and
in retinoic acid hydroxylation. CYP en-
zymes can also generate toxic metabolites
contributing to increased risk for cancer,
birth defects, and other toxic effects
(Nebert and Russell 2002).
The CYP enzymes are divided on the
basis of amino acid identity into families
(enzymes that share > 40% identity) and
subfamilies (sharing > 55% identity)
(Nebert and Russell 2002). In the evolu-
tion-based nomenclature system, the sym-
bol CYP representing cytochrome P450
is followed by an Arabic numeral denot-
ing the family, a letter designating the sub-
family (when two or more exist), and an
Arabic numeral representing the individ-
ual gene within the subfamily (Nebert et
al. 1987, Nelson et al. 1996).
In human beings, 57 CYP genes and
33 nonfunctional pseudogenes, arranged
into 18 families and 42 subfamilies, have
thus far been detected. CYP enzymes re-
sponsible for foreign compound metabo-
lism—among other functions—belong
almost exclusively to the CYP1, CYP2,
CYP3, and to a lesser degree, CYP4 fami-
lies (Nebert and Russell 2002).
The CYP1 family consists of 2 subfam-
ilies and 3 members: CYP1A1, CYP1A2,
and CYP1B1. CYP1A1 and CYP1B1 are
expressed in varying amounts in different
tissues, most efficiently metabolize poly-
cyclic aromatic hydrocarbons, and are of
little importance in drug metabolism
(Nebert and Russell 2002). CYP1A2, in
contrast, is constitutively expressed in the
liver (where it constitutes about 13% of
total liver CYP content), preferentially
metabolizes arylamines and N-heterocy-
clics, and is involved in metabolism of a
number of drugs such as caffeine, clomi-
pramine, clozapine, cyclobenzaprine, fluta-
mide, imipramine, lisofylline, mianserin,
olanzapine, ropinirole, tacrine, theophyl-
line, (R)-warfarin (Shimada et al. 1994,
Miners and McKinnon 2000, Nebert and
Russell 2002), lidocaine (Wang et al. 1999,
Wang et al. 2000), and ropivacaine (Oda
et al. 1995, Ekstrom and Gunnarsson
1996, Halldin et al. 1996). All three CYP1
enzymes detoxify or activate many envi-
ronmental carcinogens (Nebert and Rus-
sell 2002).
CYP2 is the largest CYP family in mam-
mals, and consists of 13 subfamilies and
16 members (Nebert and Russell 2002).
CYP2A6 is the best-characterized enzyme
in the CYP2A subfamily and constitutes
1 to 10% of the total liver CYP protein
(Yun et al. 1991, Shimada et al. 1994,
Pelkonen et al. 2000). It is probably the
only CYP enzyme catalyzing coumarin 7-
hydroxylation (Pelkonen et al. 2000). The
subfamily CYP2C constitutes about 20%
of total liver CYP content (Shimada et al.
1994), and human CYP2C8, CYP 2C9,
and CYP2C19 together participate in the
metabolism of more than half of drugs fre-
quently prescribed (Nebert and Russell
2002). CYP2D6 constitutes only about
2% of total liver CYP content (Shimada
et al. 1994), but metabolizes over 75 drugs
(Nebert and Russell 2002). CYP2C8,
CYP2C9, CYP2C19, and CYP2D6 are
polymorphically expressed (Nakamura et
15
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al. 1985, Wedlund et al. 1985, Dai et al.
2001, Oscarson 2001).  CYP2E1 metab-
olizes few drugs, including the muscle-re-
laxant chlorzoxazone, which also serves as
a probe drug. CYP2E1 participates, how-
ever, in the metabolism of several other
drugs, often forming toxic metabolites. It
accounts for less than 30% of formalde-
hyde formation in ethanol metabolism.
Several fluorinated volatile anesthetics are
biotransformed by CYP2E1 to reactive
metabolites and inorganic fluoride, which
are thought to be associated with halothane
hepatitis and with nephrotoxicity.
CYP2E1 also forms the N-acetyl-p-ben-
zochinonimine from paracetamol (ace-
taminophen), and mediates activation of
many carcinogens (Fuhr 2000).
The CYP3 family has four members:
CYP3A4, CYP3A5, CYP3A7, and
CYP3A43 (Nebert and Russell 2002).
CYP3A constitutes about 30% of total
CYP protein in the liver (Shimada et al.
1994). It is estimated that the metabolism
of 40 to 50% of drugs used in humans
involves CYP3A (Pelkonen et al. 1998,
Thummel and Wilkinson 1998). For ex-
ample, drugs such as quinidine, nifedipine,
felodipine, verapamil, diltiazem, lovasta-
tin, simvastatin, atorvastatin, erythromy-
cin, cyclosporine, triazolam, and mida-
zolam, and many procarcinogens are sub-
strates for CYP3A (Bertz and Granneman
1997, Kantola et al. 1998a, Neuvonen et
al. 1998, Pelkonen et al. 1998). CYP3A4
also participates in the metabolism of rop-
ivacaine (Oda et al. 1995, Ekstrom and
Gunnarsson 1996, Halldin et al. 1996).
The large interindividual variability in the
CYP3A activity reflects a genetic effect
combined with modulation by environ-
mental factors (Thummel and Wilkinson
1998).
The CYP4 family has five subfamilies
and 12 members. CYP4A11, CYP4B1,
CYP4F2, and CYP4F3 metabolize some
drugs, but mainly have other functions,
including participation in the metabolism
of fatty acids, of arachidonic acid, of leu-
kotrienes, and of prostaglandins (Nebert
and Russell 2002).
Of the extrahepatic CYP enzymes, those
expressed in the gastrointestinal tract are
of special interest. Orally administered
drugs are exposed to these enzymes dur-
ing the first-pass phase. CYP3A is the
major CYP subfamily in the human small
intestine (Kivistö et al. 1996, Zhang et al.
1999), and the CYP3A4 located in the
intestinal wall contributes markedly to the
first-pass elimination of many CYP3A4
substrates, e.g., cyclosporine (Hoppu et al.
1991, Wu et al. 1995) and midazolam
(Paine et al. 1996). The catalytic activity
of intestinal CYP3A4 does not correlate
with the catalytic activity of hepatic
CYP3A4, and a considerable inter-individ-
ual variation exists in the intestinal expres-
sion of CYP3A4 (Lown et al. 1994). Lo-
cal anesthetics are not administered orally
and thus are not markedly exposed to the
intestinal CYPs.
CYP inhibition
The mechanisms of CYP inhibition can
be divided into reversible, quasi-irrevers-
ible, and irreversible, of which reversible
inhibition is probably the most common
(Lin and Lu 1998).
Reversible inhibition can further be
divided, based on enzyme kinetics, into
competitive, noncompetitive, and uncom-
petitive.
In competitive inhibition, the inhibitor
competes with the substrate for the active
site of the free enzyme; the apparent
Michaelis-Menten constant of the sub-
strate (K
m
) increases, without a change in
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the maximum velocity of metabolism
(V
max
). The degree of inhibition depends
on the inhibitor concentration, the sub-
strate concentration, K
m
, and the inhibi-
tion constant of the inhibitor (K
i
).
In noncompetitive inhibition, the inhib-
itor binds to a different binding site of the
enzyme and has no effect on the binding
of the substrate; V
max
 decreases with no
change in K
m
. Degree of inhibition de-
pends only on inhibitor concentration and
K
i
, not on substrate concentration and K
m
.
In uncompetitive inhibition, the inhib-
itor binds to the enzyme-substrate com-
plex, not to the free enzyme; both the V
max
and K
m
 decrease to the same extent. De-
gree of inhibition depends on inhibitor
concentration, substrate concentration,
K
m
, and K
i
.
Itraconazole is an example of a revers-
ible, competitive inhibitor of CYP3A4
(von Moltke et al. 1996).  Omeprazole and
lansoprazole are both noncompetitive in-
hibitors of CYP3A-catalyzed conversion of
dextromethorphan to 3-methoxymorphi-
nan (Ko et al. 1997), and cotinine inhib-
its CYP2E1 by an uncompetitive mecha-
nism (Van Vleet et al. 2001).
In quasi-irreversible inhibition, an in-
hibitor first undergoes metabolic activa-
tion by the CYP enzyme, and then this
inhibitory metabolite forms a stable met-
abolic intermediate (MI) complex with the
prosthetic heme of CYP, making the en-
zyme functionally inactive. MI complex-
ation can be reversed in vitro, but not in
vivo, hence the name quasi-irreversible
(Lin and Lu 1998). Macrolides like eryth-
romycin and clarithromycin are examples
of compounds forming a MI complex with
CYP3A (Thummel and Wilkinson 1998).
In irreversible inhibition, a drug is ox-
idized by CYP to a reactive intermediate,
which causes irreversible inactivation of the
enzyme by covalently binding to its heme,
its protein, or both. This kind of inhibi-
tion is also called mechanism-based or
suicide inhibition (Lin and Lu 1998,
Thummel and Wilkinson 1998). For ex-
ample, ethinylestradiol, used in oral con-
traceptives, is a mechanism-based inhibi-
tor of CYP3A4 in vitro (Lin and Lu 1998).
In quasi-irreversible and irreversible
inhibition (MI complexation and mecha-
nism-based inhibition), a time-dependent
proportion of the CYP enzymes is com-
plexed or destroyed, while the remaining
enzymes show normal activity. This leads
to a time-dependent decrease in V
max
 but
no change in K
m
. Time-dependent loss of
enzyme activity is one of the most impor-
tant criteria in distinguishing between re-
versible and irreversible inhibition (Lin
and Lu 1998).
CYP induction
Induction is defined as an increase in
amount and activity of a drug-metaboliz-
ing enzyme, as a consequence of long-term
(hours and days) chemical exposure
(Pelkonen et al. 1998). From a biological
point of view, induction is an adaptive re-
sponse that protects the cells from toxic
xenobiotics by enhancing the detoxifica-
tion activity. However, induction may also
enhance toxicity by increased formation
of reactive metabolites (Lin and Lu 1998).
Many inducers are also inhibitors of the
enzymes they induce, and the inductive
effects of a single drug may be mediated
by more than one mechanism (Fuhr 2000).
Some, but not all, CYP enzymes are
inducible. In most cases, the induction is
a consequence of an increase in gene tran-
scription, but nontranscriptional mecha-
nisms also exist. For example, ethanol se-
lectively induces CYP2E1 by stabilizing
the enzyme protein (Fuhr 2000).
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The regulation of gene transcription
generally depends on inducers interacting
with certain receptors. The expression of
CYP1 genes is induced by the aryl hydro-
carbon (Ah) receptor, which dimerizes with
the Ah receptor nuclear translocator, in
response to many polycyclic aromatic hy-
drocarbons such as those found in indus-
trial incineration products, cigarette
smoke, and charcoal grilled food (Nebert
and Russell 2002, Rushmore and Kong
2002). After a sequence of events, the ap-
propriate mRNA is transcribed and trans-
lated into its corresponding protein (Lin
and Lu 1998). For example, smoking has
a dose-dependent effect on CYP1A2-de-
pendent caffeine clearance, which is in-
creased 1.2-fold, 1.5-fold, and 1.7-fold
when 1 to 5, 6 to 10, and > 10 cigarettes
are smoked per day (Tantcheva-Poor et al.
1999). Sometimes the binding of induc-
ing agents to the Ah receptor also leads to
induction of uridine diphosphate gluco-
syltransferases and glutathione-S-trans-
ferases (Lin and Lu 1998).
Three other transcriptional induction
mechanisms involve three distinct orphan
receptors (having no known endogenous
ligands, thus “orphan”): constitutive andros-
tane receptor (CAR), pregnane X receptor
(PXR), and peroxisome proliferator-activated
receptor (PPAR) (Waxman 1999, Fuhr
2000).
Induction caused by phenobarbital
seems to be mediated by CAR, with the
most pronounced effect on CYP2B6 and
clear effects also on CYP2C8, CYP2C9,
CYP3A4, and CYP1A2. Phenobarbital-
type induction often shows partial over-
lap with PXR-mediated induction (Fuhr
2000).
The rifampicin/glucocorticoid-type in-
duction appears to be mediated by PXR,
which is activated by CYP3A4 inducers
such as rifampicin and phenobarbital
(Fuhr 2000, Goodwin et al. 2002). All
CYP3A4 substrates, i.e., about half of all
drugs undergoing biotransformation in
humans, are subject to this type of induc-
tion (Fuhr 2000). Rifampicin is a potent
inducer of CYP3A4 and, for example, re-
duces the AUC of oral midazolam, triaz-
olam, and buspirone by > 90% (Backman
et al. 1996, Villikka et al. 1997, Backman
et al. 1998, Lamberg et al. 1998, Kivistö
et al. 1999).
The PPARs are divided into PPAR-al-
pha and PPAR-gamma. PPAR-alpha is
involved in the transcription of genes that
encode for proteins controlling lipopro-
tein and fatty acid metabolism, and PPAR-
gamma controls adipocyte differentiation
and adipogenesis (Fuhr 2000). PPAR-al-
pha is involved in CYP4A induction (Wax-
man 1999), and PPAR-alpha ligands like
gemfibrozil or bezafibrate lower plasma
triglyceride concentrations by 30 to 40%
and low-density lipoprotein (LDL) cho-
lesterol by 10 to 15% (Fuhr 2000).
CYP inhibition and induction in
drug-drug interactions
A change in drug metabolism is an im-
portant cause of pharmacokinetic drug-
drug interactions. An interaction may al-
ter systemic drug disposition, and, if a drug
is administered orally, also first-pass me-
tabolism (Dresser et al. 2000).
The clinical significance of a drug-drug
interaction depends on the magnitude of
change in the active parent drug and/or
active metabolite concentrations at the ef-
fect site, and on the therapeutic index of
the drug. For example, anticoagulants,
antidepressants, and cardiovascular drugs
have a narrow therapeutic index, making
patients on these drugs more prone to drug
interactions (Lin and Lu 1998).
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Clinically significant CYP inhibition
occurs only when the inhibited enzyme is
a major elimination pathway. The (un-
bound) plasma concentration of the in-
hibitor also must be sufficient. Compar-
ing the relative affinity of the substrate
(K
m
) and inhibitor (K
i
) obtained in in vit-
ro interaction studies does not necessarily
reveal the effect of the inhibitor in vivo.
The factors which have been suggested to
explain the discrepancy between in vitro
and in vivo studies include: the inhibitor
and substrate concentrations used, protein
concentration of microsomes, and artifacts
in in vitro interaction studies; differences
in the liver/plasma partition ratio in vivo;
mechanism-based inhibition; extrahepat-
ic metabolism; and active drug transport.
Moreover, induction (and irreversible in-
hibition) is dose- and time-dependent, so
the effect depends not only on the induc-
er dose, but also on the duration of ad-
ministration. Some interactions with
CYP3A4 inhibitors may also involve in-
hibition of P-glycoprotein (Lin and Lu
1998, Dresser et al. 2000).
The effect of CYP inhibition or induc-
tion depends not only on the magnitude
of decrease in the plasma concentration of
the parent drug caused by altered metabo-
lism, but also on the pharmacological ac-
tivity or toxicity of the metabolite pro-
duced, or both. For example, inhibition
of CYP2D6, which metabolizes (pro-drug)
codeine to morphine, will significantly
diminish the analgesic efficacy of codeine
(Caraco et al. 1999).
The administration route of the CYP
substrate can influence the clinical effect
of enzyme inhibition and induction, be-
cause orally administered drugs are ex-
posed to the intestinal CYPs during ab-
sorption. For example, grapefruit juice
greatly inhibits the CYP3A4 in the small
intestine and thereby impairs the intesti-
nal first-pass metabolism of orally admin-
istered CYP3A4 substrate drugs such as
lovastatin (Kantola et al. 1998b). On the
other hand, itraconazole inhibits CYP3A4
both in the gut and the liver, impairing
both the first-pass and systemic elimina-
tion of CYP3A4 substrates such as mida-
zolam (Olkkola et al. 1996). Rifampicin
seems to induce more the intestinal than
the hepatic CYPs (Hebert et al. 1992).
In drug disposition, inter-ethnic and
inter-individual differences are important.
Although the ethnic differences are not yet
fully understood, and there are many fac-
tors that contribute to the great inter-in-
dividual variation seen in drug metabo-
lism, genetic factors are important for drug
disposition. Considerable variation exists
between subjects in regard to the content
of each CYP enzyme;  the CYP2D6,
CYP2C9, and CYP2C19 polymorphisms
are especially important clinically and may
relate also to drug interactions (Lin and
Lu 1998, Lamba et al. 2002, Scordo et al.
2002).
P-glycoprotein
P-glycoprotein, a member of the adenos-
ine triphosphate (ATP) -binding cassette
transporter protein family, is a membrane
protein consisting of more than 1200
amino acids and having two homologous
halves. The physiological function of this
efflux transporter is thought to be secre-
tion of exogenous, potentially harmful
substances (Lo and Burckart 1999).
P-glycoprotein is found in the entero-
cytes of the gastrointestinal tract, the prox-
imal tubules of the kidneys, in bile calculi
of the liver, in the blood-brain barrier, the
testes, the placenta, and the hematopoiet-
ic cells. P-glycoprotein is involved in the
excretion of substances into the gut, bile,
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and urine, and is considered to play an
important role in the blood-brain, blood-
testes, and blood-placenta barriers (Lo and
Burckart 1999). The importance of P-gly-
coprotein was first recognized in the con-
text of multi-drug resistance during che-
motherapy for tumors, so the gene encod-
ing P-glycoprotein is called MDR1 (Ger-
mann 1996).
Many drugs are substrates for both
CYP3A and P-glycoprotein (Yasuda et al.
2002), which are often co-induced; recent-
ly it has been reported that PXR, a key
regulator of CYP3A transcription, has been
reported also to be involved in the regula-
tion of expression of MDR1 (Geick et al.
2001, Ekins and Erickson 2002). Both
genetic and environmental factors cause
wide interindividual differences in the ex-
pression of intestinal P-glycoprotein
(Lown et al. 1997, Geick et al. 2001).
Inhibition and induction of P-glyco-
protein contribute to a number of drug-
drug interactions. For example, inhibition
of P-glycoprotein is the mechanism behind
the reduced elimination of digoxin caused
by quinidine (Fromm 2000). It is as yet
unknown whether ropivacaine is a sub-
strate for P-glycoprotein.
Ropivacaine
Ropivacaine [S-(–)-1-propyl-2’6’-pipe-
coloxylidide] is a long-acting, enantiomer-
ically pure  amide-type local anesthetic
with a structure similar to that of bupiv-
acaine (the butyl group in bupivacaine
being replaced by a propyl group). Race-
mic bupivacaine, introduced on the mar-
ket in 1965, has for years been the most
widely used long-acting local anesthetic
(Ekblom and Widman 1966a, Ekblom
and Widman 1966b, Ruetsch et al. 2001).
In the late 1970s and early 1980s, anes-
thesiologists became more concerned
about the CNS- and cardiovascular tox-
icity of racemic bupivacaine (Albright
1979, Heath 1982, Rosenberg et al. 1983,
Kalso and Rosenberg 1984), prompting
the development of ropivacaine (McClel-
lan and Faulds 2000), which was intro-
duced on the market in 1996 (Ruetsch et
al. 2001). Ropivacaine is used for surgical
anesthesia, postoperative pain, and labor
pain management by epidural and intrath-
ecal administration, peripheral nerve
blocks, and local infiltration (Markham
and Faulds 1996, McClure 1996, McClel-
lan and Faulds 2000).
Ropivacaine is contraindicated in pa-
tients with a known sensitivity to any
amide-type local anesthetic. The manufac-
turer presently does not recommend ropi-
vacaine to be used for retrobulbar block,
paracervical block, or intravenous region-
al anesthesia, due to lack of clinical data
(AstraZeneca 2003). However, use of rop-
ivacaine has been studied for retrobulbar
and intravenous anesthesia (Hartmanns-
gruber et al. 1999, Kallio et al. 1999, Ata-
nassoff and Hartmannsgruber 2002, Peng
et al. 2002, Uy et al. 2002).
The molecular weight of ropivacaine is
274 (base), and it has a negative logarithm
of the acid ionization constant (pK
a
) of
8.1 (McClure 1996). The major portion
(94%) of ropivacaine in whole blood is
associated with plasma proteins (Lee et al.
1989).
Pharmaceutics
Ropivacaine is commercially available as
ropivacaine hydrochloride in four concen-
trations: 2 mg/mL, 5 mg/mL, 7.5 mg/mL,
and 10 mg/mL (AstraZeneca 2003). It is
compatible for use in combination with
such drugs as morphine sulphate, sufen-
tanil citrate, fentanyl citrate, and clonidine
hydrochloride (Oster Svedberg et al.
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2002).
Sometimes local anesthetic solutions are
alkalinized with the intention to increase
the speed of onset of nerve blocks. If alka-
linization is used with ropivacaine, this
should not be done until just before ad-
ministration (5-10 minutes), and alkalin-
ized ropivacaine should not be used for
infusions (Fulling and Peterfreund 2000).
Pharmacodynamics
Local anesthetics reversibly block nerve
impulse conduction by inhibiting voltage-
gated sodium channels in nerve cell mem-
branes (Butterworth and Strichartz 1990),
and, at higher doses, they inhibit gamma-
aminobutyric acid receptor type A-medi-
ated (GABA
A
-ergic) transmission and
stimulate N-methyl-D-aspartate (NMDA)
receptors (Ladd et al. 2002).
In general, lipid solubility determines
(in vitro) the potency of a local anesthetic
agent, protein binding affects the duration
of anesthesia, and pK
a
 correlates with the
onset of local anesthetic action. Potency,
in general, increases with increasing lipo-
philicity. Compounds with a high degree
of plasma protein binding also have a long
duration of action. The start of local anes-
thetic action is directly related to the
amount of drug present in the base form
at tissue pH 7.4, and thus is inversely pro-
portional to the pK
a
 of the agent (Covino
1986). Ropivacaine has a similar pK
a
 (8.1)
and plasma protein binding (94% vs.
96%), but lower relative n-heptane/buffer
partitioning (2.9:10), than does bupiv-
acaine (Rosenberg et al. 1986, Lee et al.
1989). Theoretically, then, ropivacaine
should have a similar onset time and du-
ration of action, and lower potency than
bupivacaine.
Pain is transmitted via (small myelinat-
ed) A-delta and (unmyelinated) C fibers,
and motor function is controlled by (large
myelinated) A-alpha and A-beta fibers
(McClellan and Faulds 2000). Low pK
a
and high lipid solubility favor block of A
fibers before C fibers, but the reverse is
true for high pK
a
 and low lipid solubility
(Wildsmith et al. 1989). Ropivacaine has
a pK
a
 similar to that of bupivacaine, but is
less lipid soluble. Thus, it is less likely to
penetrate large myelinated motor nerve
fibers than is bupivacaine, and is more se-
lective for nerve fibers responsible for pain
transmission than for those responsible for
motor function (Rosenberg and Heino-
nen 1983, McClellan and Faulds 2000).
Ropivacaine preferentially blocks tetro-
dotoxin-resistant sodium channels over
tetrodotoxin-sensitive sodium channels.
Because the former type sodium channels
exist mainly in the small dorsal root gan-
glions responsible for nociceptive sensa-
tion, this selective action also may under-
lie the differential block occuring with
ropivacaine (Oda et al. 2000).
All local anesthetics, with the exception
of cocaine, exhibit a biphasic effect on
vascular smooth muscle. At low concen-
trations they cause vasoconstriction, and
at higher concentrations they cause vasodi-
latation (Covino 1986). With ropivacaine,
the vasoconstrictor effect is also seen at the
concentrations used clinically. An intrad-
ermal injection of  0.063 to 0.5% ropiv-
acaine reduces skin blood flow, when com-
pared to injection of saline (Cederholm et
al. 1992).
Toxicity
The cardiotoxicity of bupivacaine provid-
ed the impulse to develop a new local an-
esthetic agent, ropivacaine (McClure
1996). Because of  their mechanism of
action, i.e., the inhibition of voltage-gat-
ed ion channels, all local anesthetics can
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produce toxic CNS effects and direct and
indirect cardiovascular effects (Mather and
Chang 2001). Clinical signs of cardiovas-
cular changes occur at considerably great-
er local anesthetic plasma concentrations
than do those causing CNS toxicity (Scott
et al. 1989). Among long-acting local an-
esthetics, ropivacaine and levobupivacaine
are less toxic than bupivacaine (Mather and
Chang 2001).
CNS toxicity. The most common bupi-
vacaine- or ropivacaine-induced CNS tox-
icity symptoms are visual and hearing dis-
turbances, dysarthria, tingling, perioral
numbness, dizziness, paresthesia, light-
headedness, muscular twitching, and mus-
cular rigidity (Knudsen et al. 1997).
Healthy volunteers tolerated up to 4.3 mg/
L (range 3.4-5.3) total and 0.56 mg/L
(0.34-0.85) free arterial ropivacaine con-
centrations when ropivacaine was admin-
istered intravenously at 10 mg/min. The
respective venous concentrations were 2.2
(0.5-3.2) mg/L and 0.15 mg/L (0.01-
0.24). Generally, toxic symptoms are re-
lated to free arterial concentrations rather
than venous concentrations. Peripheral
venous concentrations depend on the per-
fusion of the region the vessel is draining,
and tend to peak later than the arterial (or
brain) concentrations (Tucker 1986). With
no significant difference in dosage (115
vs. 103 mg), the free arterial ropivacaine
plasma concentrations tolerated were
about twice as high as with bupivacaine
(0.56 vs. 0.30 mg/L) (Knudsen et al.
1997).
In a study by Scott et al. (1989) healthy
volunteers tolerated 25% more ropivacaine
than bupivacaine (both given intravenous-
ly at a rate of 10 mg/min) without CNS
symptoms. This was almost certainly an
underestimation of the difference between
these drugs, since the maximal dose (150
mg) allowed by the protocol was reached
with ropivacaine on 7 of 12 occasions and
with bupivacaine on 1 of 12 occasions
(Scott et al. 1989).
Cardiotoxicity. Studied in rabbit heart,
ropivacaine is less cardiodepressant and
arrhythmogenic than bupivacaine (Pit-
känen et al. 1992). Ropivacaine also dis-
turbs mitochondrial energy metabolism in
rat-heart isolated mitochondria less than
does bupivacaine (Sztark et al. 1998).
Toxicity of the metabolites. The thresh-
old for CNS toxicity of unbound plasma
concentration of PPX in rats is about one-
twelfth that of unbound ropivacaine (Eka-
todramis et al. 2003).
Levobupivacaine vs. ropivacaine. In
1999, another new long-acting local anes-
thetic, levobupivacaine, the S(–)-enanti-
omer of racemic bupivacaine, became
commercially available (Foster and
Markham 2000). Both of these new drugs,
ropivacaine and levobupivacaine, have less
cardiovascular and CNS toxicity than
bupivacaine (McClellan and Faulds 2000).
CNS toxicity in sheep (Santos and
DeArmas 2001, Ladd et al. 2002) and car-
diac toxicity in swine (Morrison et al.
2000), in sheep (Santos and DeArmas
2001), and in rats (Ohmura et al. 2001) is
reported to rank in the order of: bupiv-
acaine > levobupivacaine > ropivacaine.
On the other hand, when administered by
left intracoronary arterial infusion in
sheep, no significant differences appeared
in survival or in fatal dose between bupiv-
acaine, levobupivacaine, and ropivacaine
(Chang et al. 2001). In the rat study by
Ohmura et al. (2001), the CNS toxicity
of levobupivacaine and ropivacaine was
similar and less than that of bupivacaine.
In an isolated, crystalloid-perfused
guinea pig heart preparation, levobupiv-
acaine was less cardiotoxic in causing atri-
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oventricular dissociation than were R(+)-
bupivacaine and racemic bupivacaine.
However, ropivacaine affected the atrio-
ventricular delay even less than did
levobupivacaine (Graf et al. 2002).
In the guinea pig heart preparation,
ropivacaine reduced contractility signifi-
cantly less than did bupivacaine, indepen-
dently of its isomeric form (Graf et al.
2002). In rat heart, as well, there was no
stereospecific effect of bupivacaine isomers
on mitochondrial bioenergetics (Sztark et
al. 2000).
In an isolated rabbit heart, racemic
bupivacaine, levobupivacaine, and ropiv-
acaine induced an increase in QRS dura-
tion at a respective ratio of 1:0.4:0.3 (Ma-
zoit et al. 2000), and in anesthetized swine
at a ratio of 2.1:1.4:1 (Morrison et al.
2000). In open-chest dogs, the unbound
plasma concentrations at cardiovascular
collapse were 5.7 (3-11) mg/L for bupiv-
acaine, 9.4 (5-18) mg/L for levobupiv-
acaine, and 20 (10-39) mg/L for ropiv-
acaine. Mortality after resuscitation at-
tempts was 50%, 30%, and 10% (Groban
et al. 2001). In swine, cardiotoxicity based
on lethal dose was at a ratio of 2.1:1.2:1
(Morrison et al. 2000).
Inhibition of basal and epinephrine-
stimulated cyclic adenosine monophos-
phate (cAMP) production may contribute
to local anesthetic cardiovascular toxicity.
In volunteers, bupivacaine inhibited more
potently basal cAMP production than did
ropivacaine, and was as potent as ropiv-
acaine at inhibiting epinephrine-stimulat-
ed cAMP production. Inhibition of cAMP
production may limit the success of resus-
citation attempts from local anesthetic-re-
lated cardiovascular toxicity (Butterworth
et al. 1993). Further, milrinone was more
effective than epinephrine in resuscitating
pigs from ropivacaine-induced cardiovas-
cular toxicity (Neustein et al. 2000).
Clinical cases. In nine cases of ropiv-
acaine-induced convulsions reported in the
literature (Plowman et al. 1998, Ala-Kok-
ko et al. 2000a, Muller et al. 2001,
Petitjeans et al. 2002), the total venous
plasma concentrations of ropivacaine
ranged from 1.4 mg/L at 30 minutes to
6.0 mg/L (free 0.66 mg/L) at 40 minutes
after the episode. One of these patients,
after sciatic block with 225 mg ropiv-
acaine, also suffered severe cardiac dys-
rhythmia with a prolonged QRS interval
(Ruetsch et al. 1999). The total and un-
bound venous plasma concentrations of
ropivacaine 7 minutes after administration
of ropivacaine were 3.6 and 0.69 mg/L,
respectively, and the estimated concentra-
tions at the time of cardiac arrhythmia
were 7.5 and 1.5 mg/L.
Two mothers scheduled for elective
Caesarean section under epidural anesthe-
sia received accidental intravenous injec-
tions of 75 mg and of 150 mg ropivacaine
without serious adverse effects (Morton et
al. 1997).
Potency
In animal studies, ropivacaine and bupiv-
acaine were equally potent in terms of
block of evoked action potential in vitro
and minimum effective concentration in
vivo. Ropivacaine was longer-acting than
bupivacaine on infiltration, equally effec-
tive in sciatic and brachial plexus block,
and a bit shorter-lasting in epidural and
spinal anesthesia (Akerman et al. 1988).
Levobupivacaine seems to be equipo-
tent with bupivacaine, but the equipoten-
cy of ropivacaine with bupivacaine in man
has been questioned (Foster and Markham
2000). Ropivacaine and levobupivacaine
have not been compared clinically.
Based on a study of minimum local
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analgesic concentrations of epidural
levobupivacaine relative to racemic bupi-
vacaine in women in labor, the potency
ratio levobupivacaine: bupivacaine was
0.98 with regard to the commercial prep-
arations and 0.87 in molar terms, neither
figure statistically significant (NS) (Lyons
et al. 1998). In two studies comparing the
minimum local analgesic concentrations
of epidural ropivacaine and  bupivacaine
in labor, the analgesic potency of ropiv-
acaine to bupivacaine was 0.60  (Capogna
et al. 1999, Polley et al. 1999). The rela-
tive motor blocking potency of epidural
ropivacaine to bupivacaine in labor has
been 0.66 (Lacassie et al. 2002).
An editorial accompanying the study
by Polley et al. (D’Angelo and James 1999)
discussed many questions concerning that
study. For example, the median effective
dose (ED
50
) values estimated did not in-
clude information regarding the slope or
the shape of the dose-response curve, or
the dose producing the desired effect in
95% of that population (ED
95
) (D’Angelo
and James 1999). Because the dose-re-
sponse curves are typically sigmoid, dif-
ferences in potency may appear smaller at
the higher concentrations clinically used
than found by ED
50
 studies (Graf et al.
2002). The ED
50
 of epidural bupivacaine
has, moreover, varied considerably in dif-
ferent studies, perhaps reflecting variations
in patient populations or uncontrolled
variables like parity (D’Angelo and James
1999).
Some studies have found no difference
between the analgesic potency of ropiv-
acaine and bupivacaine in labor (Owen et
al. 1998, Owen et al. 2002), but ropiv-
acaine with fentanyl has been associated
with less motor block than bupivacaine
with fentanyl (Meister et al. 2000). In ad-
dition, the ED
50
 volume of 5 mg/mL
ropivacaine for blocking the femoral nerve
in adults undergoing knee arthroscopy is
similar to that of bupivacaine (Casati et
al. 2001).
In “equipotent doses” in piglets, ropiv-
acaine 6 mg/kg and bupivacaine 4 mg/kg
induced similar hemodynamic alterations,
but ropivacaine had less effect on ventric-
ular conduction (Lefrant et al. 2001). In
rats, as well, intravenous ropivacaine 4.5
mg/kg/min was less toxic than bupivacaine
3 mg/kg/min (Dony et al. 2000).
Despite the possible difference in rela-
tive potencies of bupivacaine, levobupiv-
acaine, and ropivacaine, some authors have
considered ropivacaine to be the safest
long-acting local anesthetic presently avail-
able (Graf 2001, Wang et al. 2001). How-
ever, appropriate safety steps should always
be taken to ensure safe use of any local
anesthetic (Mulroy et al. 1997).
Pharmacokinetics
Absorption
Absorption of local anesthetics is primari-
ly and directly related to local blood flow,
and inversely related to local tissue bind-
ing (Tucker 1986). Mean total and free
plasma concentrations of ropivacaine af-
ter various routes of administration are
presented in Appendix 1. Systemic absorp-
tion of epidural ropivacaine is biphasic and
can be described by two parallel first-or-
der rate processes. An initial fast phase with
a half-life of 14 minutes is followed by a
slower phase with a half-life of 4.2 h. The
terminal t
½
 of 4.3 h of ropivacaine after
epidural administration corresponds well
with the slower phase absorption half-life
of 4.2 h, indicating that its absorption is
the rate-limiting step in elimination of
ropivacaine after epidural injection (Eman-
uelsson et al. 1997a).
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Local tissue perfusion depends on site
of injection, and decreases in the order
intercostal > epidural > brachial plexus
(Tucker 1986, Thomas and Schug 1999).
This can also been seen with ropivacaine
from the reported half-lives after different
routes of administration (Appendix 1).
The extent of systemic absorption of
ropivacaine after an epidural injection,
calculated from total arterial and venous
AUCs, is 98% and 87% respectively
(Emanuelsson et al. 1997a).
Distribution
Ropivacaine has a V
ss
 of about 42 L (0.6
L/kg) in healthy volunteers, and is 94 to
95% bound to plasma proteins (mainly
AAG) (Lee et al. 1989, Arlander et al.
1998). The plasma-protein binding of rop-
ivacaine increases with increasing AAG
concentration during a continuous post-
operative epidural infusion (Erichsen et al.
1996, Scott et al. 1997), as is also seen with
bupivacaine (Veering et al. 2002). After
epidural administration, ropivacaine cross-
es the placenta (Irestedt et al. 1997).
After both intravenous and epidural
administration, the arterial plasma concen-
trations increase faster than do venous con-
centrations, and the equilibrium is reached
within 20 min after the end of the infu-
sion (Knudsen et al. 1997).
Elimination
Ropivacaine undergoes mainly oxidative
hepatic metabolism in humans, with about
1% of an intravenous dose excreted un-
changed in the urine, and has a CL of 0.4
to 0.5 L/min and t
1/2
 of about 1.9 h (Lee
et al. 1989, Halldin et al. 1996) (Appen-
dix 1).
Ropivacaine is metabolized to 3-OH-
ropivacaine mainly by CYP1A2, and to
PPX mainly by CYP3A4 (Oda et al. 1995,
Ekstrom and Gunnarsson 1996). After a
15-minute intravenous infusion of 50 mg
radioactive [14C]ropivacaine in healthy
volunteers, 86% of the total radioactivity
was excreted in urine, and 8% in feces,
within 96 hours. In urine, 43% of the orig-
inal dose was identified as representing: 3-
OH-ropivacaine (37%), PPX (3%), 3-
OH-PPX (2%), ropivacaine (1%), and 4-
OH-ropivacaine (0.4%). The majority
(80%) of the dose was excreted in urine
within 24 hours (Halldin et al. 1996).
Hydroxylated metabolites are prone to
subsequent Phase II conjugation reactions
(Falany et al. 1999). No evidence exists of
metabolic racemization of the ropivacaine
metabolites (Arvidsson et al. 1995).
Drug interactions
At the time this study began, there appar-
ently were no controlled studies on the
effects of drug interactions or liver disease
on the pharmacokinetics of ropivacaine.
While this study was in progress, Arland-
er et al. (1998) reported that the CYP1A2
inhibitor fluvoxamine 25 mg twice daily
for 2 day reduced ropivacaine CL by 68%,
and that the CYP3A4 inhibitor ketocona-
zole 100 mg twice daily for 2 days reduced
ropivacaine CL by 15%.
Clinical use
Epidural anesthesia and analgesia
The pharmacokinetic and pharmacody-
namic characteristics of epidural ropiv-
acaine are similar to those of epidural bupi-
vacaine (Katz et al. 1990). However, the
motor block produced by ropivacaine is
of slower onset, shorter duration, and low-
er intensity than a block produced by the
same concentration of bupivacaine (Brock-
way et al. 1991), and epidural ropivacaine
has a shorter terminal t
½
 than bupivacaine’s
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(Sandler et al. 1998). After an epidural
block with 150 mg ropivacaine 10 mg/mL,
increasing age is associated with a more
cephalic spread of  the block, a more in-
tense motor blockade, and an increase in
the incidence of bradycardia and hypoten-
sion (Simon et al. 2002).
An epidural infusion of  ropivacaine 10
to 30 mg/h for 21 hours in healthy volun-
teers has been reported to be safe (Eman-
uelsson et al. 1995). After major orthope-
dic surgery, an epidural infusion of 2 mg/
mL and 3 mg/mL ropivacaine 10 mL/h
for 72 hours provided similar pain relief
without toxic symptoms, but 3 mg/mL
produced a more intense motor block
(Burm et al. 2000).
During a continuous epidural infusion
of 2 mg/mL ropivacaine (mean 15 mg/h)
for 120 hours, the C
max
 of free ropivacaine
was 0.096 ± 0.034 µg/L (and total plasma
concentration 4.1 ± 1.2 mg/L) and the
highest individual free plasma concentra-
tion was 0.16 mg/L (Wiedemann et al.
2000).
A combination of an epidural opioid
and a local anesthetic has had a synergis-
tic effect in laboratory trials (Kaneko et al.
1994). However, addition of ropivacaine
1 mg/mL to epidural fentanyl 10µg/mL
for postoperative pain after hip replace-
ment surgery did not reduce the need for
epidural fentanyl significantly (Kosta-
movaara et al. 2001).
Labor
In labor epidural analgesia, both ropiv-
acaine and bupivacaine provide proper la-
bor analgesia with no significant differenc-
es in the incidence of spontaneous vaginal
delivery or other obstetric and neonatal
outcomes, if the drugs are used at equipo-
tent and clinically relevant (low) doses
(Halpern and Walsh 2003, Polley and
Columb 2003). For example, ropivacaine
0.8 mg/mL plus fentanyl 2 µg/mL effec-
tively initiates epidural analgesia during
labor, while preserving the mother’s abili-
ty to void and ambulate (Campbell et al.
2000). In addition, when ropivacaine is
combined with sufentanil, the minimal
local analgesic concentration of ropiv-
acaine in the first stage of labor falls from
0.13% to 0.09% (Palm et al. 2001).
Debon et al. (2002) have recently re-
ported a circadian rhythm-related varia-
tion in the duration of epidural ropivacaine
analgesia during labor, with the shortest
duration in the evening (7 PM – 1 AM) and
maximal (28% longer) duration in the af-
ternoon (1 PM – 7 PM). Analgesia duration
in the morning (7 AM – 1 PM) was also
longer than in the evening. At night (1 AM
– 7 AM) the duration was shorter than in
the morning or afternoon (NS). Proposed
mechanisms behind this variation are cir-
cadian changes in membrane nerve cell
permeability, cell potassium concentration,
catecholamine release, or hormonal factors
(Debon et al. 2002).
Epidural 0.5% ropivacaine for cesare-
an section provides surgical anesthesia sim-
ilar to that provided by 0.5% bupivacaine,
without compromising the uteroplacental
circulation (Alahuhta et al. 1995).
Children
Ropivacaine has been safely used for cau-
dal epidural anesthesia in children (Da
Conceicao and Coelho 1998, Ivani et al.
1998, Da Conceicao et al. 1999, Koinig
et al. 1999, Lönnqvist et al. 2000). For
single-injection caudal epidural block, 1
mL/kg of 2 mg/mL ropivacaine produces
reliable analgesia for inguinal surgery in
children. Clonidine 2 µg/kg or ketamine
0.5 mg/kg can be used to prolong the an-
algesia 2- to 3-fold (Morton 2000).
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Epidural ropivacaine via lumbar cathe-
ter has been used safely in infants and
young children (McCann et al. 2001), and
continuous epidural infusion of 2 mg/mL
ropivacaine at a rate of 0.4 mg/kg/h has
been studied in children aged 3.5 months
to 8 years, and provided good analgesia
with few side effects. In neonates and in-
fants, however, this infusion rate was not
recommended to be used for more than
36 to 48 h (Hansen et al. 2000).
During a continuous epidural ropiv-
acaine-sufentanil infusion, epinephrine 2
µg/mL has been a useful adjuvant to low-
er the need for sufentanil and ropivacaine
(Kokki et al. 2002).
Following caudal epidural administra-
tion in children, ropivacaine undergoes a
slower systemic absorption than bupiv-
acaine (Ala-Kokko et al. 2000b, Karmakar
et al. 2002), and after lumbar epidural
administration of ropivacaine, C
max
 in chil-
dren occurs later than in adults. Proposed
reasons for this include direct effects of
local anesthetics on epidural blood flow,
effects of general anesthesia (in children)
on epidural regional blood flow, and ef-
fects of age on absorption (McCann et al.
2001).
Brachial plexus block
Ropivacaine 5 mg/mL and bupivacaine 5
mg/mL for an axillary plexus block were
similar in clinical and pharmacokinetic
comparisons (Vainionpää et al. 1995).
Ropivacaine 7.5 mg/mL (40mL) produced
axillary plexus block of similar onset and
duration, but of better quality, than did
bupivacaine 5.0 mg/mL (40 mL) (Raeder
et al. 1999). In uremic and nonuremic
patients, ropivacaine 300 mg (50 mL) pro-
duced an axillary block of similar quality
without systemic toxicity (Pere et al. 2003).
Addition of epinephrine to ropivacaine
does not alter absorption after brachial
plexus block (Hickey et al. 1990). How-
ever, addition of clonidine 150 µg to 40
mL of ropivacaine 7.5 mg/mL for a bra-
chial plexus block prolonged motor and
sensory block and analgesia without in-
creased incidence of side-effects (El Saied
et al. 2000).
A 48-h continuous interscalene infu-
sion of 6 or 9 mL/h ropivacaine 2 mg/
mL, started 6 hours after an interscalene
block with 30 mL ropivacaine 7.5 mg/mL,
provided satisfactory pain relief postoper-
atively after major shoulder surgery, and
was well tolerated (Ekatodramis et al.
2003). After elective hand or forearm sur-
gery, however, a continuous axillary ropi-
vacaine infusion was no more beneficial
than saline in relieving postoperative pain
(Salonen et al. 2000).
Sciatic Nerve Block
In combination with 15 mL mepivacaine
20 mg/mL for a femoral nerve block, 20
mL of 5 mg/mL ropivacaine and 20 mL
of 5 mg/mL levobupivacaine for a sciatic
nerve block provide comparable surgical
anesthesia and postoperative analgesia (Ca-
sati et al. 2002).
Spinal anesthesia
Ropivacaine was not originally registered
for spinal anesthesia, and its safety was first
studied for inadvertent intrathecal injec-
tion during epidural anesthesia (van Kleef
et al. 1994, Wahedi et al. 1996). Ropiv-
acaine is now indicated also for spinal an-
esthesia (AstraZeneca 2003). However,
intrathecal isobaric ropivacaine 15 mg for
transurethral resection of the bladder or
prostate was less potent than isobaric bupi-
vacaine 10 mg (Malinovsky et al. 2000),
and the relative potency for hyperbaric
ropivacaine versus bupivacaine in spinal
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anesthesia in healthy volunteers was 1:2
(McDonald et al. 1999).
Intravenous Regional Anesthesia
Although not officially indicated, ropiv-
acaine has also been studied for intrave-
nous regional anesthesia. Ropivacaine 1.8
mg/kg and lidocaine 3 mg/kg produced
similar anesthesia, but ropivacaine had a
longer-lasting residual effect. Safety for this
indication could not be established be-
cause of the small sample size, but more
people in the lidocaine group than in the
ropivacaine group reported light–headed-
ness and hearing disturbance at the time
of cuff deflation (Chan et al. 1999). In
another study, ropivacaine 2 mg/mL for
intravenous regional anesthesia was also
associated with fewer CNS side-effects
than was lidocaine 5 mg/mL (Atanassoff
and Hartmannsgruber 2002).
Other forms of anesthesia
After hernia repair in ilioinguinal blocks,
0.25 mL/kg ropivacaine 5mg/mL has been
successfully used for postoperative pain
(Wulf et al. 1999).
Ropivacaine 7.5 mg/mL (30 mL) has
been safely applied as wound infiltration
(10 mL) plus drain lavage (20 mL) after
major shoulder surgery (Horn et al. 1999),
and a continuous intra-articular ropiv-
acaine infusion has also improved analge-
sia for minor surgery, when combined with
a brachial plexus block (Klein et al. 2001).
However, intra-articular ropivacaine pro-
vides postoperative analgesia inferior to
that of interscalene brachial plexus block
after arthroscopic shoulder surgery (Lau-
rila et al. 2002).
Ropivacaine 10 mg/mL was successfully
used in peribulbar block with similar re-
sults as 7.5 mg/mL bupivacaine, with a
tendency to a faster start of block with
ropivacaine (Nociti et al. 1999).
After bilateral intercostal blockade in
healthy volunteers, terminal t
½
 and senso-
ry blockade were shorter with 56 mL rop-
ivacaine 2.5 mg/mL than with equal dose
of bupivacaine (Kopacz et al. 1994).
Intra-articular injection of 20 mL rop-
ivacaine 5 mg/mL does not reduce pain
more effectively than does 20 mL saline
after knee arthroscopy (Rautoma et al.
2000, Santanen et al. 2001).
There is one report of temporary is-
chemia of the glans penis 40 minutes after
dorsal penile nerve block with 0.75% rop-
ivacaine (Burke et al. 2000). Ischemia was
successfully treated with an iloprost (PGI
2
analogue) intravenous infusion.
Other uses
Ropivacaine, like lidocaine, is reported to
be beneficial in patients with ulcerative
colitis (Arlander et al. 1996). The mecha-
nism of action is not clear. No significant
changes in concentrations of eicosanoids
or neuropeptides were observed after rop-
ivacaine administration (Hillingso et al.
2002). Another study, however, found that
ropivacaine markedly reduced tumor ne-
crosis factor-alpha-induced leukocyte ad-
hesion and tissue recruitment, making it
possibly useful in controlling acute inflam-
mation (Zhang and Thorlacius 2000).
CYP inhibitors studied
Fluvoxamine
Fluvoxamine is a selective serotonin
reuptake inhibitor used widely in the man-
agement of depression (Perucca et al.
1994). It has little or no effect on other
monoamine reuptake mechanisms (Figg-
itt and McClellan 2000).
Pharmacokinetics
Fluvoxamine is almost completely ab-
sorbed from the gastrointestinal tract. It
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undergoes extensive oxidative metabolism,
primarily by the hepatic CYP enzymes
CYP2D6 and CYP1A2 (Spigset et al.
1995, Carrillo et al. 1996), with only 3%
of an oral dose excreted unchanged in the
urine. Because of extensive first-pass me-
tabolism, it has an oral bioavailability of
about 50% (Figgitt and McClellan 2000).
After repeated doses, fluvoxamine dis-
plays nonlinear pharmacokinetics. The
C
max
 is about 73 µg/L after repeated ad-
ministration of 100 mg/day, with the
steady state reached in about 10 days. It
has a volume of distribution of 25 L/kg,
and is 77% bound to plasma proteins (Fig-
gitt and McClellan 2000).
Interactions
Fluvoxamine is a potent inhibitor of
CYP1A2, but may inhibit also CYP2C19,
CYP3A4, CYP2C9, and CYP2D6, and is
involved in many drug-drug interactions
(van Harten 1995, Figgitt and McClellan
2000, Olesen and Linnet 2000, Madsen
et al. 2001).
Ciprofloxacin
Ciprofloxacin, introduced in the 1980s,
is a broad-spectrum fluoroquinolone an-
tibacterial agent showing excellent activi-
ty against most Gram-negative bacteria
(Davis et al. 1996). The quinolones are
unique among antimicrobial agents in that
they target bacterial topoisomerases, arrest-
ing deoxyribonucleic acid (DNA) replica-
tion. Although newer quinolones have
been developed, ciprofloxacin remains the
most potent quinolone against Pseudomo-
nas aeruginosa (Walker 1999).
Pharmacokinetics
After a single oral dose of 250 mg ciprof-
loxacin, the C
max
 in healthy volunteers is
1.2 mg/L, t
max
 0.8  h, t
½
 5.4 hours, and V
ss
231 L. About 40% of the dose is recov-
ered in the urine (Lubasch et al. 2000).
Interactions
Ciprofloxacin is an inhibitor of CYP1A2
(Bertz and Granneman 1997) and, for ex-
ample, significantly reduces the elimina-
tion of theophylline (Wijnands et al. 1986,
Batty et al. 1995), caffeine (Harder et al.
1988), and clozapine (Raaska and Neu-
vonen 2000).
Erythromycin
Erythromycin, introduced in 1952, is a
macrolide derived from Streptomyces eryth-
reus. It inhibits ribonucleic acid (RNA) -
dependent protein synthesis by reversibly
binding to the 50 S ribosomal subunits of
susceptible microorganisms, and shows
excellent activity against atypical respira-
tory pathogens and the Legionella species
(Brittain 1987, Alvarez-Elcoro and Enzler
1999).
Pharmacokinetics
Erythromycin has a bioavailability of
about 50% and is 75% to 90% bound to
plasma proteins. (Yu et al. 2001) The ap-
parent volume of distribution is 0.6 L/kg
(Zhanel et al. 2001). In healthy volunteers
(Caucasians), a single oral dose of 500 mg
erythromycin given as an encapsulated
enteric-coated pellet produced a C
max
 of
2.3 mg/L at a t
max
 of 3.0 h (2.0–4.0). The
oral clearance was 66 L/h and the t
½
 1.5 h
(Yu et al. 2001). Erythromycin is primari-
ly excreted in the bile, with only 2% to
5% excreted in urine (Alvarez-Elcoro and
Enzler 1999).
Interactions
Erythromycin inhibits CYP3A4 and in-
teracts with many drugs (Periti et al. 1992,
Bertz and Granneman 1997). For exam-
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ple, erythromycin has reduced the CL of
intravenously administered midazolam by
approximately 50% (Olkkola et al. 1993),
and increased the AUC of orally adminis-
tered buspirone and simvastatin 6-fold
(Kivistö et al. 1997, Kantola et al. 1998c).
Clarithromycin
Clarithromycin is a relatively new mac-
rolide antibiotic which is structurally sim-
ilar to erythromycin (Alvarez-Elcoro and
Enzler 1999). It differs from erythromy-
cin by the methylation of the hydroxyl
group at position 6 on the lactone ring
(Rodvold 1999). Clarithromycin, as does
erythromycin, inhibits the protein synthe-
sis of susceptible bacteria by reversible
binding of the 50 S ribosomal subunits of
the 70 S ribosome. Compared with eryth-
romycin, clarithromycin has a somewhat
broader spectrum of microbiologic activi-
ty (Alvarez-Elcoro and Enzler 1999). It also
has shown increased activity against H.
influenzae, due to its active 14-hydroxyl
metabolite (Zhanel et al. 2001).
Pharmacokinetics
Clarithromycin has a bioavailability of
about 50%. The apparent volume of dis-
tribution is 190 to 310 L (about 3-4 L/
kg), and plasma protein binding 42% to
72%. After oral administration of a single
500 mg-dose of clarithromycin, a C
max
 of
about 2 mg/L is reached after 2 to 3 hours
(Rodvold 1999). At steady state, with oral-
ly administered dosages of 250 mg and 500
mg every 12 hours, C
max
 is 1 mg/L and 2
to 3 mg/L, respectively (Alvarez-Elcoro
and Enzler 1999).
Clarithromycin is extensively metabo-
lized, with CYP3A-dependent 14-hydrox-
ylation and oxidative N-demethylation
being the most important pathways. Of
the metabolites, the 14-hydroxyclarithro-
mycin possesses antibacterial activity.
Elimination of clarithromycin is nonlin-
ear and dose-dependent. The apparent oral
clearance after multiple doses of 250 mg
tablets in adults has ranged between 29 and
41 L/h. The t
½
 of clarithromycin after
multiple doses of 250 mg is close to 4 h,
and after multiple doses of 500 mg about
5 h, and the t
½ 
of the active metabolite 14-
hydroxyclarithromycin about 6 and 8 h,
respectively (Rodvold 1999). These pro-
longed half-lives, compared with erythro-
mycin, allow twice-daily dosing (Alvarez-
Elcoro and Enzler 1999).
Interactions
Clarithromycin is primarily metabolized
by CYP3A, and potent inhibitors of
CYP3A such as ketoconazole and ritonavir
alter the metabolism of clarithromycin
(Rodvold 1999). Clarithromycin, itself, is
an inhibitor of CYP3A4 (Bertz and Gran-
neman 1997), and has interactions with
such drugs as astemizole, cisapride, pi-
mozide, terfenadine, midazolam, triaz-
olam, carbamazepine, cyclosporine,  and
omeprazole (Rodvold 1999).
Itraconazole
Itraconazole, synthesized in 1980, is a tri-
azole antifungal drug with activity against
most human fungal pathogens, including
Aspergillus sp (Grant and Clissold 1989).
Pharmacokinetics
In healthy fasting volunteers, a capsule
formulation of itraconazole has a bioavail-
ability of 40%, and a 100 mg dose results
in a C
max
 of 0.02 mg/L within 1.5 to 4 h
(Grant and Clissold 1989). Taking the
drug with food increases its plasma con-
centrations and improves treatment results
(Wishart 1987). In blood, itraconazole is
95% bound to plasma proteins, primarily
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to albumin; 5% is bound to blood cells,
and only 0.2% of the drug is free (Grant
and Clissold 1989). Plasma binding is not
altered by changes in plasma albumin or
AAG concentrations (Arredondo et al.
1994). After a single oral 100 mg or 200
mg dose in healthy volunteers, it has a ter-
minal t
½
 of approximately 20 h. At steady
state, after repeated administration of itra-
conazole 100 mg to 400 mg daily, the t
½
is prolonged to about 30 h. Itraconazole
undergoes extensive hepatic metabolism,
and is excreted as its metabolites via bile
and urine (Grant and Clissold 1989). The
main metabolite, hydroxy-itraconazole,
also has considerable antifungal activity
(Willems et al. 2001).
Interactions
Itraconazole causes a large rise in the plas-
ma concentration of many drugs which
are substrates of CYP3A4 (Venkatakrish-
nan et al. 2000), like midazolam (Olkkola
et al. 1994, Olkkola et al. 1996), triazolam
(Varhe et al. 1994, Neuvonen et al. 1996),
quinidine (Kaukonen et al. 1997), felo-
dipine (Jalava et al. 1997), lovastatin (Neu-
vonen and Jalava 1996), simvastatin (Neu-
vonen et al. 1998), methylprednisolone
(Varis et al. 1998, Varis et al. 1999), cy-
closporine (Schafer-Korting 1993), and
buspirone (Kivistö et al. 1997, Kivistö et
al. 1999).
CYP inducers studied
Rifampicin
Rifampicin, a synthetic derivative of rifa-
mycin B which was developed in the
1960s, specifically inhibits bacterial RNA
polymerase by forming a stable drug-en-
zyme complex (Wehrli 1983). Adminis-
tered in combination with other drugs for
4 to 12 months, it is used primarily in the
treatment of tuberculosis (Venkatesan
1992, Douglas and McLeod 1999).
Pharmacokinetics
The bioavailability of oral rifampicin af-
ter a single dose is 93%, but after a 3-week
treatment, its bioavailability falls to 68%
(Loos et al. 1987), probably due to auto-
induction of rifampicin metabolism (Ven-
katesan 1992). About 80% of rifampicin
is bound to protein (mainly albumin) in
plasma (Acocella 1978). After administra-
tion of a single 600-mg dose, the peak se-
rum concentration of about 10 mg/L oc-
curs in 2 h, and the t
½
 is about 2.5 h (Aco-
cella 1978). Because the capacity of the
liver is saturated with doses over 300 to
450 mg, further increasing the dose there-
fore results in a more than proportional
increase in serum concentrations (Acocel-
la 1978).
Interactions
Rifampicin is a potent inducer of hepatic
(Combalbert et al. 1989) and intestinal
CYP3A4 (Kolars et al. 1992), and is in-
volved in many clinically important drug-
drug interactions (Strayhorn et al. 1997).
Rifampicin can also induce CYP1A2,
CYP2A6, CYP2B6, CYP2C8, CYP2C9,
CYP2C19, and CYP3A5 enzymes, but
their inducibility by rifampicin is less than
that of CYP3A4 (Bachmann and Jauregui
1993, Chang et al. 1997, Sumida et al.
2000, Gerbal-Chaloin et al. 2001, Rae et
al. 2001, Niemi et al. 2003). Furthermore,
P-glycoprotein (Schuetz et al. 1996) and
some Phase II reactions, e.g., the glucu-
ronidation of lorazepam (Bachmann and
Jauregui 1993) and propafenone (Dilger
et al. 2000), are induced by rifampicin.
Induction of CYP3A4 by rifampicin is
mediated by PXR.
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Cigarette smoking
Cigarette smoking is a major health con-
cern worldwide. In Finland, in the year
2001, 29% of adult males and 20% of
adult females smoked daily (Helakorpi et
al. 2001). Polycyclic aromatic hydrocar-
bons in tobacco smoke are responsible for
inducing CYP1A1 and CYP1A2 (Zevin
and Benowitz 1999), an effect mediated
by intracellular Ah-receptors (Fuhr 2000).
CYP1A2 activity rises dose-dependently by
smoking up to nearly 2-fold when more
than 20 cigarettes are smoked per day
(Tantcheva-Poor et al. 1999). Also
CYP2E1 is possibly induced by cigarette
smoke (Zevin and Benowitz 1999).
Interactions
Cigarette smoking induces biotransforma-
tion and reduces plasma concentrations of
drugs metabolized by CYP1A2, such as
caffeine, clozapine, tacrine, theophylline,
and fluvoxamine (Spigset et al. 1995,
Zevin and Benowitz 1999).
Liver disease
The liver is the main organ responsible for
the metabolism of drugs. In liver disease,
absorption, distribution, and elimination
of drugs may be changed (Hayes 1992).
Absorption of local anesthetics is directly
related to local blood flow, and inversely
related to local tissue binding to proteins
and adipose tissue at the injection site
(Tucker 1986, Thomas and Schug 1999).
Distribution can be influenced by chang-
es in total body water and plasma proteins,
and elimination may be altered by abnor-
mal liver blood flow and impaired meta-
bolic capacity (Hayes 1992). The effect of
hepatic blood flow and enzyme activity,
and of drug plasma protein binding, on
the CL of a drug varies with its E
H
 (Tuck-
er 1994). Because of the relatively low E
H
of ropivacaine, its CL is not very suscepti-
ble to changes in the hepatic blood flow
and depends mostly on hepatic enzyme
activity and plasma protein binding, while
the unbound (intrinsic) clearance depends
only on enzyme activity (Tucker 1994).
In the liver, CYP3A4 and CYP1A2, the
enzymes responsible for the metabolism
of ropivacaine, constitute about 30% and
13% of the total amount of CYP enzymes
(Shimada et al. 1994). These enzymes sit-
uated predominantly in the centrilobular
area of the hepatic lobule are more prone
to hypoxia and appear to be more affected
in liver disease than are enzymes in the
periportal area (Hayes 1992).
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Ropivacaine is used for surgical anesthe-
sia and postoperative pain management by
epidural administration, peripheral nerve
blocks, and local infiltration (McClure
1996). It is metabolized to 3-OH-ropiv-
acaine mainly by CYP1A2, and to PPX
mainly by CYP3A4 (Ekstrom and Gun-
narsson 1996). High ropivacaine plasma
concentrations, for example due to altered
pharmacokinetics, can lead to toxic CNS
or cardiovascular symptoms (Ohmura et
al. 2001).
CYP-related drug interactions are
known to affect the pharmacokinetics of
many drugs. Fluvoxamine and ciproflox-
acin are known inhibitors of CYP1A2
(Fuhr et al. 1992, Rasmussen et al. 1995),
and erythromycin, clarithromycin, and
itraconazole inhibit CYP3A4 (Thummel
and Wilkinson 1998). Moreover, oral con-
traceptive steroids may inhibit CYP1A2
(Balogh et al. 1995, Laine et al. 1999).
Rifampicin induces, among other CYP
isozymes, CYP3A4 (Venkatesan 1992),
and cigarette smoking induces CYP1A2
(Zevin and Benowitz 1999).
The liver is the main organ responsible
for the metabolism of drugs. In liver dis-
ease, altered absorption, distribution, and
elimination can influence drug pharma-
cokinetics (Hayes 1992).
At the time this study began, to the best
of our knowledge, no controlled studies
were available concerning the effects of
drug interactions or liver disease on the
pharmacokinetics of ropivacaine. While
this study was in progress, Arlander et al.
(1998) reported the effect of two CYP in-
hibitors on the pharmacokinetics of ropi-
vacaine.
The specific aims were to study the effect on
the pharmacokinetics of intravenous ropiv-
acaine of the following factors:
1. Fluvoxamine, ciprofloxacin, erythromy-
cin, clarithromycin, and itraconazole
(Studies I, II, IV).
2. Combined fluvoxamine and erythromy-
cin (II).
3. Rifampicin and cigarette smoking (III).
4. Oral contraceptive steroids (I-IV).
5. End-stage liver disease (V).
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Subjects
The healthy volunteers involved in all
Studies (I–V) were 26 females and 18
males (Table 1 and Appendix 2). The pa-
tients were 7 females and 6 males with
chronic end-stage liver disease being eval-
uated for liver transplantation. Before en-
tering the studies, volunteers were ascer-
tained to be healthy by medical history,
clinical examination, and a 12-lead elec-
trocardiogram. Before inclusion in Study
V, both volunteers and patients underwent
laboratory screening including hematolog-
ical and biochemical blood tests.
None of the healthy volunteers was on
continuous medication, except that 17
women were taking oral contraceptive ste-
roids. Most of the patients used some
medications, mostly for their liver disease.
One patient was on ciprofloxacin plus pro-
pranolol, another on fluconazole plus pro-
pranolol, and two others on propranolol.
The 12 volunteers who smoked tobacco
were not allowed to do so on test days,
except in Study III where the effect of
smoking was evaluated. In none of the
Table 1. Mean characteristics of subjects in Studies I to V
Study Subjects Female/ Age Weight Smoker Contraceptive
No. Male (years (kg (yes/ steroid users
(No.) ± SD) ± SD) no) (No.)
I Healthy volunteers 4/4 26 ± 7 76 ± 12 4/4 2
II Healthy volunteers 6/2 25 ± 8 68 ± 11 4/4 4
III Healthy volunteers 9/9 24 ± 4 65 ± 9 8/10 5
IV Healthy volunteers 7/2 23 ± 5 64 ± 10 0/9 4
V Healthy volunteers 5/3 24 ± 2 66 ± 12 0/8 4
V Patients withliver disease 7/6 42 ± 12 67 ± 14 1/12 0
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studies were the volunteers allowed to
drink grapefruit juice, alcohol, coffee, tea,
or cola on the test days. There were no
restrictions concerning smoking, eating, or
drinking for the patients with chronic end-
stage liver disease in Study V.
Study designs
The studies were carried out between May
1998 and June 2001 in the Department
of Anesthesiology and Intensive Care Med-
icine and the Department of Clinical Phar-
macology, University of Helsinki.
Studies I to IV were placebo-controlled,
randomized, double-blind, and cross-over
in design, to assess the effect of clarithro-
mycin, itraconazole, erythromycin, fluvox-
amine, and rifampicin on the pharmaco-
kinetics of ropivacaine (Table 2). Study III
was also designed to compare the phar-
macokinetics of ropivacaine in smokers
and nonsmokers. Study V was an open
parallel group study to assess the effect of
chronic end-stage liver disease on the phar-
macokinetics of ropivacaine.
All trials were carried out in the post-
anesthesia care units of the Helsinki Uni-
versity Central Hospital. At the end of each
pretreatment period in Studies I to IV, and
without any pretreatment medication in
Study V, an intravenous infusion of 0.6
mg/kg ropivacaine hydrochloride
(Naropin, AstraZeneca, Södertälje, Swe-
den) was given over 30 minutes starting
between 9 AM and 10 AM.
Blood and urine sampling
In Studies I to IV, for each subject, a vein
of the forearm contralateral to the ropiv-
acaine infusion was cannulated with a plas-
tic cannula and kept patent with an obtu-
rator. Timed blood samples (10 mL) were
drawn into heparinized tubes before and
at 25, 30, 45, 60, 75, and 90 minutes, and
at 2, 3, 4, 5, 6, 8, 10, and 12 hours after
the start of ropivacaine administration.
Table 2. Structure of Studies I to V
Study Study No. of Pretreatment medication, daily dose, Wash-out period
no. type phases and duration in cross-over studies (weeks, minimum)
or grouping variable in parallel studies
I x-over 3 clarithromycin 500 mg for 4 days 4
itraconazole 200 mg for 4 days
II x-over 4 erythromycin 1.5 g for 6 days 3
fluvoxamine 100 mg for 5 days
both erythromycin and fluvoxamine
III x-over 2 rifampin 600 mg for 5 days 6
parallel smoking
IV x-over 2 ciprofloxacin 1 g for 2.5 days 2
V parallel chronic end-stage liver disease
x-over = study is randomized, double-blind, and cross-over in design;
parallel = open parallel group study
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Plasma was separated within 2 hours and
stored at -20 °C until analysis. Urine was
collected cumulatively in fractions of 0 to
12 and 12 to 24 hours after the start of
the infusion.
In Study V, venous blood samples were
collected before and at 5, 10, 20, 30, 35,
40, 45, 60, 75, and 90 min and at 2, 3, 4,
5, 6, 8, 10, and 12 hours after the start of
ropivacaine administration. Additional
samples from patients with liver disease
were collected at 16, 18, and 22 hours.
Plasma was separated within 2 hours and
stored at -20 °C until analysis. Urine was
collected before and at intervals of 0 to 4,
4 to 8, 8 to 12, 12 to 16, and 16 to 24
hours after the start of the ropivacaine in-
fusion. Urine volumes were measured and
aliquots were taken from each fraction and
stored at -20 °C until analysis.
Determination of plasma drug
concentrations
Ropivacaine
In Studies I to III, concentrations of rop-
ivacaine were determined by gas chroma-
tography with etidocaine as an internal
standard (Engman et al. 1998). The quan-
titation limit was 1 µg/L for plasma and 5
µg/L for urine. The inter-day coefficient
of variation (CV) at relevant concentra-
tions was < 6%.
In Study IV, concentrations of ropiv-
acaine were determined by liquid chroma-
tography with lidocaine as an internal stan-
dard (Arvidsson et al. 1995). For plasma,
the quantitation limit was 4 µg/L and in-
ter-day CV < 4%. In urine, both non-con-
jugated and total (non-conjugated plus
conjugated) concentrations of ropivacaine
were measured. To measure the total con-
centrations, conjugates in urine samples
(1.0 mL) were hydrolyzed before the chro-
matography with 1 mL of 5 N hydrochlo-
ric acid for 60 minutes at 90°C. The quan-
titation limit was 5 µg/L for the non-con-
jugated and 12 µg/L for the total ropiv-
acaine, and intra-day CV < 8%.
In Study V, total plasma concentrations
of ropivacaine were determined in all sam-
ples by gas chromatography with a nitro-
gen-sensitive detector (Engman et al.
1998). The quantitation limit was 2.7 µg/
L, with an inter-day CV < 9%. Unbound
(free) plasma concentrations of ropivacaine
were assayed by liquid chromatography
and mass spectrometric detection. The
quantitation limit was 2.7 µg/L with an
intra-day CV < 4%. The quantitation limit
was 27 µg/L, and the inter-day CV < 4%.
The urinary ropivacaine was assayed by
liquid chromatography and mass spec-
trometry (Yvonne Askemark, personal
communication, May 15, 2003).
3-OH-ropivacaine
In Studies II to IV, concentrations of 3-
OH-ropivacaine were determined by liq-
uid chromatography, with lidocaine as an
internal standard (Arvidsson et al. 1995).
In Studies II and III, the quantitation limit
was 2 µg/L and inter-day CV < 8%.
In Study IV, the quantitation limit for
plasma was 4 µg/L and inter-day CV < 9%.
In urine, both non-conjugated and total
(non-conjugated plus conjugated) concen-
trations of 3-OH-ropivacaine were mea-
sured, as described above for ropivacaine.
In Study V, total plasma concentrations
of unconjugated 3-OH-ropivacaine were
assayed using liquid chromatography and
mass spectrometric detection. The quan-
titation limit was 2.9 µg/L and inter-day
CV < 9%. After acid hydrolysis, the uri-
nary 3-OH-ropivacaine was assayed by liq-
uid chromatography and mass spectrom-
etry. The quantitation limit was 200 µg/
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L, and the inter-day CV was < 4% (Yvonne
Askemark, personal communication, May
15, 2003).
PPX
In Studies I to III, concentrations of PPX
were determined by gas chromatography
with etidocaine as the internal standard
(Engman et al. 1998). The quantitation
limit was 2 µg/L for plasma and 5 µg/L
for urine. The inter-day CV was < 10% at
relevant concentrations.
In Study IV, concentrations of PPX
were determined by liquid chromatogra-
phy with lidocaine as the internal standard
(Arvidsson et al. 1995). For plasma the
quantitation limit was 4 µg/L and inter-
day CV < 9%. In urine, both non-conju-
gated and total (non-conjugated plus con-
jugated) concentrations of PPX were mea-
sured, as described above for ropivacaine.
In Study V, total plasma concentrations
of PPX were assayed by liquid chromatog-
raphy and mass spectrometric detection.
The quantitation limit was 2.3 µg/L and
inter-day CV < 10%. Unbound (free) plas-
ma concentrations of PPX were also as-
sayed by liquid chromatography and mass
spectrometry. The quantitation limit was
2.3 µg/L, with an intra-day CV < 6%. Uri-
nary PPX was assayed by liquid chroma-
tography and mass spectrometry. The
quantitation limit was 70 µg/L, and the
inter-day CV < 5% (Yvonne Askemark,
personal communication, May 15, 2003).
Clarithromycin
In Study I, plasma concentrations of
clarithromycin (samples at 0, 1.5, 4, and
8 hours after the start of ropivacaine ad-
ministration) were measured by liquid
chromatography with roxithromycin as the
internal standard (Laakso et al. 1990) (Gr-
gurinovich and Matthews 1988). The limit
of quantification was 0.2 mg/L and the
intra-day CV was 1.1% at 0.88 mg/L.
Itraconazole
In Study I, plasma concentrations of itra-
conazole and OH-itraconazole (at 0 and
12 hours) were measured by liquid chro-
matography with R51012 as the internal
standard (Remmel et al. 1988, Allenmark
et al. 1990). The limit of quantification
was 10 µg/L, and the inter-day CV for itra-
conazole was 3.9% at 190 µg/L and the
CV for OH-itraconazole 2.9% at 191 µg/
L.
Erythromycin
In Study II, plasma concentrations of
erythromycin (at 0, 0.25, 1.5, 4, 8, and
12 hours) were measured by liquid chro-
matography with roxithromycin as the
internal standard (Laakso et al. 1990). The
limit of quantitation was 0.5 mg/L, and
the inter-day CV was 3.6% at 3.9 mg/L.
Fluvoxamine
In Study II, plasma concentrations of flu-
voxamine (at 0, 2, 6, and 12 hours) were
measured by liquid chromatography with
haloperidol as the internal standard (Van
der Meersch-Mougeot and Diquet 1991).
The limit of quantitation was 10 µg/L, and
the inter-day CV was 4.5% at 86 µg/L.
Ciprofloxacin
The plasma concentrations of ciprofloxa-
cin in Study IV (samples before and at 1,
2, 5, 8, and 12 hours after the start of rop-
ivacaine administration) were measured by
liquid chromatography mass spectrome-
try, modifying the method described by
Kamberi et al. (1998), with ofloxacin as
the internal standard. The quantitation
limit was 20 µg/L, and the intra-day CV
10% at 0.1 mg/L and 6.2% at 0.7 mg/L.
37
Materials and methods
Pharmacokinetic calculations
The C
max
 and t
max
 of ropivacaine, PPX, and
3-OH-ropivacaine were taken directly
from each plasma concentration-time pro-
file. The AUC was estimated by means of
the logarithmic trapezoidal rule with ex-
trapolation to infinity. With the metabo-
lites, no extrapolation was done, and the
AUC was calculated for up to 12 hours
(AUC
0-12
). For each subject, the terminal
log-linear phase of the plasma ropivacaine
concentration-time curve was identified
visually and the elimination rate constant
(k
el
) determined by regression analysis. The
t
½
 of ropivacaine was calculated from the
equation: t
½
 = ln2/k
el
. The ropivacaine CL
was computed from CL = dose/AUC, and
V
ss
 from V
ss 
= MRT · CL. MRT was cal-
culated from MRT = AUMC/AUC - t/2,
where t is the infusion time (0.5 h), and
AUMC is the area under the first moment
of the plasma concentration-time curve,
calculated by the logarithmic trapezoidal
rule with extrapolation to infinity. The E
H
was estimated for ropivacaine from the
formula: E
H
 = CL/(C
p
/C
b
) · 1/hepatic
blood flow, where C
p
/C
b
 was 0.69 (Lee et
al. 1989), and hepatic blood flow was as-
sumed to be 1.35 L/min (Rowland and
Tozer 1995) in the healthy volunteers.
The cumulative fraction of unchanged
ropivacaine excreted in the urine (f
e
) and
the excretion (fraction metabolized, f
m
) of
the metabolites (f
m,3-OH
 and f
m,PPX
) were
calculated by A
e
/dose (in micromoles),
with A
e
 being the total amount excreted
in the urine.
The pharmacokinetic variables for
Studies I to IV were calculated by the phar-
macokinetic program MKMODEL (ver-
sion 5.0, Biosoft, Cambridge, U.K.), and
for Study V with WinNonlin, version 3.3
(Pharsight Corporation, Palo Alto, CA,
USA) and SAS, version 8.2 (SAS Institute,
Cary, NC, USA).
Safety assessment
The length of the heart-rate corrected (Ba-
zett 1920) QT-interval  was measured in
Studies I and II from a 12-lead electrocar-
diogram recorded before and at 0.5, 1, 2,
and 4 hours, and in Study III before and
at 0.5 and 2 hours after the start of ropiv-
acaine infusion. A 3-lead electrocardio-
gram was monitored for 6 (Study I), 3
(Studies II and III), or 1 (Studies IV and
V) hour after the start of the infusion, and
symptoms of CNS toxicity were assessed
by means of informal (Studies I – IV) or
standardized (Study V) questions. In Study
V, pulse and noninvasive blood pressure
were monitored for one hour after the start
of the infusion.
Statistical analysis
In Studies I, II, and IV, analysis of vari-
ance was used to determine the contribu-
tion of each treatment to overall variance.
A posteriori testing was done with Tukey’s
test. The Pearson product-moment corre-
lation coefficient was used to investigate
any relationship between pretreatment
plasma drug concentration and change in
the AUC of ropivacaine in Studies I and
IV. In Study IV, the t
max
 data were com-
pared by the Wilcoxon signed-rank test.
In Study III, for comparisons of all
pharmacokinetic parameters between the
smokers and nonsmokers, the two-sample
separate variance t-test was used. Placebo
and rifampicin phases were analyzed sep-
arately. The paired samples t-test was used
for comparisons between the placebo and
rifampicin phases, separately for nonsmok-
ers and smokers.
In Study V, the Wilcoxon signed-rank
test served in comparison of all pharma-
cokinetic parameters between the patients
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and healthy volunteers.
In the combined placebo phases of
Studies I to IV, analysis of variance with a
general linear model was used to determine
the contribution of study, sex, contracep-
tive steroid use, and smoking to overall
variance in CL, AUC, C
max
, t
1/2
, V
ss
, f
e
, f
m,3-
OH
, and f
m,PPX
. A posteriori testing was done
with Tukey’s test.
Results were expressed as means ± stan-
dard deviation (SD), except in figures
showing pharmacokinetics in Studies I to
IV, in which mean values ± standard error
of the means were used for clarity. Differ-
ences were regarded as significant if P <
0.05. In Studies I to IV, data were ana-
lyzed with the statistical program Systat
for Windows, versions 6.0.1 and 7.0.1
(SPSS Inc., Chicago, IL, USA), and in
Study V, SAS version 8.2 (SAS Institute).
In Figures 1 to 3, data are presented as
box-and-whiskers plots. Boxes show the
inter-quartile range: the edges mark the
first and third quartiles (i.e., the central
50% of the values fall within the range of
the box), and the central vertical lines mark
the medians. The whiskers show the range
of values that fall within 2.5 inter-quartile
ranges. Outside values, within 4 inter-
quartile ranges, are plotted with asterisks,
and far outside values, outside 4 inter-
quartile ranges, are plotted with small cir-
cles.
Ethical considerations
All study protocols were conducted ac-
cording to the revised Declaration of Hel-
sinki (WMA 2000), and were approved
by the appropriate ethics committees ac-
cording to current regulations. The pro-
tocols of Studies I to III and V were ap-
proved by the Ethics Committee of the
Department of Surgery, Helsinki Univer-
sity Central Hospital, Helsinki, and the
protocol of Study IV by the Ethics Com-
mittee for Studies in Healthy Subjects of
the Hospital District of Helsinki and Uusi-
maa. In addition, the Finnish National
Agency for Medicines was notified of all
the studies. All subjects received both oral
and written information and gave their
written informed consent before entering
the studies.
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Results
Effect of CYP inhibitors and
inducers on the
pharmacokinetics of
intravenous ropivacaine
(Studies I-IV)
Clarithromycin (Study I)
Compared with placebo, a 4-day pretreat-
ment with 250 mg clarithromycin twice
daily appeared to raise mean plasma con-
centrations of ropivacaine (NS, Fig. 1).
However, no statistically significant chang-
es took place in the pharmacokinetic pa-
rameters of the parent ropivacaine.
Clarithromycin reduced both the C
max
 and
the AUC
0-12
 of PPX by 44% (P < 0.01),
and the ratio of AUC
0-12
 of PPX to that of
ropivacaine by 49% (P < 0.001). The f
m,PPX
was reduced by 48% (NS).
Itraconazole (Study I)
As with clarithromycin, a 4-day pretreat-
ment with 100 mg itraconazole once dai-
ly seemed to raise the mean plasma con-
centrations of ropivacaine (NS, Fig. 1),
with no statistically significant changes in
the pharmacokinetic parameters of ropiv-
acaine. However, both the C
max
 and the
AUC
0-12
 of PPX were reduced by 74% (P
< 0.001) by itraconazole, and the ratio of
AUC
0-12
 of PPX to that of ropivacaine re-
duced by 79% (P < 0.001)—significantly
more than by clarithromycin (49%, P <
0.05). The f
m,PPX 
was reduced by 75% (P <
0.05) by itraconazole.
Fluvoxamine (Study II)
A 5-day pretreatment with fluvoxamine
100 mg daily raised both the AUC and
the MRT of ropivacaine 3.7-fold (P <
0.001 and P < 0.01, respectively), pro-
longed the t
½
 from 2.3 hours to 7.4 hours
(P < 0.01), and reduced both the CL and
the E
H
 by 77% (P < 0.001; Fig. 1). Flu-
voxamine also raised the AUC
0-12 
of  PPX
2.5-fold (P < 0.001) and the C
max
 of PPX
2.8-fold (P < 0.001) and reduced the plas-
ma concentrations of 3-OH-ropivacaine
to below the limit of quantitation.
In urine, fluvoxamine raised the f
m,PPX
4.8-fold (P < 0.001) and reduced the
f
m,3-OH
 by 73% (P < 0.001).
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Figure 1. Effect of erythromycin plus fluvoxamine (EF), fluvoxamine (Flu), ciprofloxacin (Cip), itraconazole (Itr),
clarithromycin (Cla), erythromycin (Ery), and rifampicin (Rifa) on pharmacokinetics of ropivacaine in Studies I to IV.
Ratios of individual ropivacaine CL, AUC, Cmax, t½, Vss, fe, fm,3-OH, and fm,PPX during the medications to their respective
values during placebo are presented as box-and-whisker plots.
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Erythromycin (Study II)
Pretreatment with 500 mg erythromycin
three times daily for 6 days had only mi-
nor effects on the pharmacokinetics of
ropivacaine (Fig. 1). It raised the f
m,3-OH
 by
23% (P < 0.05). The V
ss
 was significantly
increased after erythromycin pretreatment
(69 L vs. 53 L after placebo, P < 0.01).
Erythromycin plus fluvoxamine
(Study II)
Pretreatment with a combination of flu-
voxamine and erythromycin, when com-
pared with fluvoxamine alone, further
raised the AUC of ropivacaine by 50% (P
< 0.01) and the MRT by 64% (P < 0.01),
and prolonged the t
½
 from 7.4 hours to
12 hours (P < 0.01; Fig. 1). Ropivacaine
CL was further reduced from 95 mL/min
to 59 mL/min (NS). The f
m,PPX
 fell by 58%
(P < 0.001), compared with the result from
the fluvoxamine pretreatment alone. The
combination also brought the AUC
0-12
 and
C
max
 of PPX down to about the same level
as with placebo.
Ciprofloxacin (Study IV)
A 2.5-day pretreatment with 500 mg
ciprofloxacin twice daily raised the ropiv-
acaine AUC by 22% (NS) and reduced
the CL by 31% (P < 0.05; Fig. 1), with no
significant change in C
max
, t
1/2
, or V
ss
.
Ciprofloxacin raised the excretion of non-
conjugated ropivacaine in urine by 79%
(P < 0.05) and f
e
 by 60% (P < 0.05).
Ciprofloxacin reduced the AUC
0-12
 of
3-OH-ropicacaine by 38% (P < 0.05). The
C
max
 fell by 53% (P < 0.01), without a sig-
nificant change in t
max
. Ciprofloxacin pro-
longed the t
1/2
 of 3-OH-ropivacaine by
46% (P < 0.05), and reduced the total
amount of 3-OH-ropivacaine in urine by
27% (P < 0.05).
With ciprofloxacin, the AUC
0-12
 of PPX
rose by 71% (P < 0.01) and C
max
 by 60%
(P < 0.01). The t
max
 was prolonged from
4.5 to 6.4 hours (NS). Because the termi-
nal log-linear phase of the plasma drug
concentration-time curve was not reached
in all subjects during the ciprofloxacin
phase, the mean t
1/2
 value could not be
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calculated. Ciprofloxacin  raised the mean
total amount of PPX in urine by 97% (P
< 0.01) .
Cigarette smoking (Study III)
Moderate smokers smoking on average 14
(median 13, range 10–20) cigarettes per
day had a 19% higher mean ropivacaine
CL (NS), and excreted in their urine 31%
more 3-OH-ropivacaine (P < 0.05) and
62% less PPX (P < 0.05) than did non-
smokers. After a 5-day pretreatment with
600 mg rifampicin daily, smokers excret-
ed in their urine 64% more 3-OH-ropiv-
acaine (P < 0.05) and 50% less PPX (P <
0.05), and had a 126% higher AUC ratio
of 3-OH-ropivacaine (P < 0.05) and 31%
lower AUC ratio of PPX (P < 0.05), than
did nonsmokers.
Rifampicin (Study III)
After a pretreatment with 600 mg rifampi-
cin once daily for 5 days, plasma ropiv-
acaine concentrations were considerably
lower both in nonsmokers and in smokers
(presented collectively in Fig. 1). Rifampi-
cin reduced the AUC of ropivacaine in
nonsmokers by 52% (P < 0.001) and in
smokers by 38% (P < 0.05), raised the CL
of ropivacaine by 93% (P < 0.001) and
47% (P < 0.01), and shortened the t
½
 of
ropivacaine by 25% (P < 0.01) and 20%
(P < 0.05). Rifampicin also reduced the
MRT by 36% (P < 0.01) and 33% (P <
0.01), reduced the C
max
 by 28% (P < 0.01)
and 9% (NS), and raised the E
H
 by 93%
(P < 0.001) and 46% (P < 0.01).
Rifampicin pretreatment considerably
lowered the plasma concentrations of 3-
OH-ropivacaine in smokers, and particu-
larly, in the nonsmokers. Rifampicin low-
ered the AUC
0-12
 of 3-OH-ropivacaine by
86% (P = 0.001) and 67% (P = 0.001) in
nonsmokers and smokers, respectively, and
reduced the C
max
 by 70% (P = 0.001) and
42% (P = 0.001). Rifampicin shortened
the t
1/2
 of 3-OH-ropivacaine in nonsmok-
ers from 2.0 to 1.2 h (P < 0.01) and in
smokers from 2.4 to 1.3 h (P = 0.01).
Rifampicin also reduced the amount of 3-
OH-ropivacaine excreted in urine by 74%
(P < 0.001) in nonsmokers and 68% (P <
0.001) in smokers (Figure 4). The f
m,3-OH
fell from 0.30 to 0.08 and from 0.39 to
0.12.
In both groups, plasma concentrations
of PPX were much higher after rifampicin
pretreatment than after placebo. Rifampi-
cin raised the AUC
0-12
 of PPX by 131%
(P < 0.001) in nonsmokers and 245% (P
< 0.001) in smokers, and raised the C
max
by 166% (P < 0.001) and 282% (P <
0.001). Rifampicin also shortened the t
1/2
from 11.3 to 6.7 h (P < 0.01) and from
8.1 to 5.0 h (P < 0.01), and enlarged the
f
m,PPX
 from 0.05 to 0.10 (P < 0.01) and
0.02 to 0.05 (P = 0.01), respectively.
Effect of chronic end-stage
liver disease on the
pharmacokinetics of
intravenous ropivacaine
(Study V)
Compared with the respective parameters
in the healthy volunteers, the patients with
chronic end-stage liver disease had a 60%
lower total CL (131 vs. 331 mL/min, P =
0.001), a 56% lower unbound CL (2.8 vs.
6.3 L/min, P = 0.002), a 57% higher V
ss
(89 vs. 56 l, P = 0.03), a 4-fold longer t
½
(11 vs. 2.6 h, P < 0.001), a 4.8-fold longer
MRT (14 vs. 2.9 h, P < 0.001), and a 3-
fold higher ropivacaine AUC (5.5 vs. 1.9
mg · L-1 · h, P < 0.001). No significant
differences appeared between the patients
and healthy volunteers in the C
max
 (total
0.71 vs. 0.87 mg/L, free 37 vs. 41 µg/L,
respectively) or in the unbound fraction
(4.8% vs. 5.7%) of ropivacaine.
No significant differences existed in the
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C
max
 of PPX (total 19 vs. 26 µg/L, free 11
µg/L vs. 13 µg/L) between the patients
with liver disease and the healthy volun-
teers. However, the concentrations of the
total and free PPX were still increasing at
22 hours in 7 and 5 patients.
In the patients, 3-OH-ropivacaine
could be detected in only one plasma sam-
ple in one patient (4 µg/L at 2 hours). In
the healthy volunteers, the C
max
 of 3-OH-
ropivacaine was 15 ± 7 µg/L, and was
reached at 2 hours in all individuals. Pa-
tients had 59% lower f
m,3-OH
 than did the
healthy volunteers (11% vs. 27%, P <
0.001).
Safety assessment
In Study V, one patient had ventricular
extrasystolia, and another described a tin-
gling feeling in her tongue during the study
day. No other adverse events were associ-
ated with the ropivacaine infusions.
Summary of results
Results of Studies I to IV are summarized
in Figure 1. Results given below are statis-
tically significant, unless indicated to be
NS.
Effect of CYP1A2 inhibitors
(Studies II and IV)
Fluvoxamine (100 mg once daily for 5
days) reduced the ropivacaine CL by 77%,
and ciprofloxacin (500 mg twice daily for
2.5 days) by 31%. Fluvoxamine also pro-
longed the ropivacaine t
1/2 
from 2.3 to 7.4
hours. Both fluvoxamine and ciprofloxa-
cin raised ropivacaine f
e
 (NS for ciprof-
loxacin), raised f
m,PPX
, and reduced f
m,3-OH
.
Effect of CYP3A4 inhibitors
(Studies I and II)
Itraconazole (200 mg once daily for 4
days), clarithromycin (250 mg twice daily
for 4 days), and erythromycin (500 mg
three times daily for 6 days) reduced the
ropivacaine CL by 13%, 5%, and 10% (all
NS). They all reduced f
m,PPX 
(NS for
clarithromycin and erythromycin), and
erythromycin  raised f
m,3-OH 
(which was not
measured after itraconazole and clarithro-
mycin pretreatments).
Combined effect of CYP1A2 and
CYP3A4 inhibitors (Study II)
The combination of  fluvoxamine (100 mg
once daily for 5 days) and erythromycin
(500 mg three times daily for 6 days) re-
duced the ropivacaine CL by 86%, raised
ropivacaine f
e
, raised f
m,PPX
 (NS), and re-
duced f
m,3-OH
.
Effect of CYP inducers (Study III, and
Studies I–IV combined)
Moderate smokers in Study III (smok-
ing a median 13 cigarettes daily) had a
19% higher ropivacaine CL than non-
smokers (NS), and excreted in urine 31%
more 3-OH-ropivacaine and 62% less
PPX than did nonsmokers. All smokers in
combined Studies I to IV (smoking a me-
dian 5 cigarettes daily) had a 5% higher
ropivacaine CL (NS), but a 18% longer
t
1/2
, a 143% higher f
e
 (NS), and a 17%
higher f
m,3-OH
 (NS) than did nonsmokers
(Table 3 and Fig. 2).
Rifampicin (600 mg once daily for 5
days, in Study III) elevated ropivacaine CL
by 93% and 47% in nonsmokers and
smokers. In both groups, rifampicin ele-
vated f
m,PPX
, and lowered f
m,3-OH
.
Effect of chronic end-stage liver
disease (Study V)
Patients with chronic end-stage liver dis-
ease had a 60% lower CL, a 56% lower
unbound CL, a 57% higher V
ss
, a 4-fold
longer t
½
, and a 3-fold higher AUC of rop-
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ivacaine, compared with the respective
parameters in healthy volunteers. The rop-
ivacaine C
max
 was similar in both groups.
Patients had a higher f
e
 and a lower f
m,3-OH
than did the healthy volunteers. In both
groups, the f
m,PPX
 was similar.
Effect of gender (Studies I–IV
combined)
After placebo pretreatments in Studies I
to IV, women (those not on contraceptive
steroids) had a 11% lower CL, a 22% long-
er t
1/2
, and a 13% higher f
e 
than did men
(All NS, Table 4). Likewise, there was no
significant difference in f
m,PPX
 or f
m,3-OH
.
Effect of oral contraceptive steroids
(Studies I–IV combined)
Female volunteers on oral contraceptive
steroids (OC) in Studies I to IV had a 49%
lower CL, a 106% higher AUC, a 71%
longer t
1/2
, a 36% lower f
m,3-OH
, and a 336%
higher f
m,PPX 
than did females not using
contraceptive steroids (P < 0.001 for all,
parameters in Table 4).
Effect of Study (Studies I–IV
combined)
Ropivacaine AUC was significantly high-
er in the placebo phase of Study IV (2.2
mg · L-1 · h), than in that of Study III (1.5
mg · L-1 · h, P < 0.05).
Table 3. Effect of smoking on pharmacokinetics of ropivacaine in Studies I to IV. Pharmacokinetic parameters of
ropivacaine in 26 nonsmokers (15 female, 11 male) and 12 smokers (7 female, 5 male; median consumption: 5
cigarettes daily) after placebo pretreatment in Studies I to IV. One female nonsmoker, one female smoker, and one male
smoker each participated in two studies, and one female smoker in three studies.
Nonsmokers Smokers
N Mean SD N Mean SD
CL (mL/min) 27 396 156 16 417 196
AUC (mg · L-1 · h) 27 1.73 0.83 16 1.91 1.12
C
max
 (mg/L) 27 0.86 0.28 16 0.90 0.20
t
½
 (h) 27 2.1 0.7 16 2.5 1.4 *
V
ss
 (L) 27 51 10 16 56 15
f
e
27 0.00 0.00 16 0.01 0.01
F
m,3-OH
23 0.29 0.09 12 0.34 0.08
F
m,PPX
27 0.04 0.03 16 0.04 0.04
* Smokers significantly different from nonsmokers (P < 0.05)
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Figure 2. Effect of smoking on pharmacokinetics of ropivacaine in Studies I to IV. Individual ropivacaine CL, AUC,
Cmax, t½, Vss, fe, fm,3-OH, and fm,PPX values in 15 female (black-outlined boxes with whiskers) and 11 male (gray-outlined
boxes) nonsmokers (no), and 7 female and 5 male smokers (yes), in placebo phases of Studies I to IV. One female
nonsmoker, one female smoker, and one male smoker each participated in two studies, and one female smoker in three
studies.
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Figure 3. Effect of oral contraceptive steroids on the pharmacokinetics of ropivacaine in Studies I to IV. Individual
ropivacaine CL, AUC, C
max
, t
½
, V
ss
, f
e
, f
m,3-OH
, and f
m,PPX
 values in 22 female (black-outlined boxes with whiskers) and 16
male (gray-outlined boxes) volunteers in placebo phases of Studies I to IV. One male volunteer participated in two
studies. Of the 8 females not using contraceptive steroids (no OC), one participated in 2 studies and one in 3 studies,
and of the 13 females on oral contraceptive steroids (OC) one participated in two studies. One female used a
subcutaneous hormonal implant (SC).
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Table 4. Effect of oral contraceptive steroids on pharmacokinetics of ropivacaine in Studies I to IV. Pharmacokinetic
parameters of ropivacaine in 22 female and 16 male volunteers in placebo phases of Studies I to IV. One male volunteer
participated in two studies. Of the 8 females not using contraceptive steroids (no OC), one participated in 2 studies and
one in 3, and of the 13 females on oral contraceptive steroids (OC), one participated in two studies. One female used a
subcutaneous hormonal implant (SC).
Males Females
No OC No OC OC SC
N Mean SD N Mean SD N Mean SD N Mean
CL (mL/min) 17 512 135 11 456 129 14 233 94 * 1 376
AUC (mg · L-1 · h) 17 1.36 0.35 11 1.32 0.52 14 2.72 1.05 * 1 1.41 †
C
max
 (mg/L) 17 0.84 0.15 11 0.84 0.25 14 0.94 0.35 1 0.78
t
½
 (h) 17 1.6 0.3 11 1.9 0.3 14 3.3 1.2 * 1 2.2
V
ss
 (L) 17 53 9 11 52 9 14 54 17 1 53
f
e
17 0.00 0.01 11 0.01 0.01 14 0.01 0.01 1 0.00
F
m,3-OH
13 0.35 0.07 9 0.35 0.05 12 0.22 0.07 * 1 0.38 †
F
m,PPX
17 0.02 0.01 11 0.02 0.01 14 0.08 0.04 * 1 0.04
* OC significantly different from no OC, P < 0.001
† SC significantly different from OC, P < 0.05
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Discussion
Methodological considerations
A power analysis was performed before
each study to calculate the number of sub-
jects sufficient to reveal in each study a
potentially clinically significant pharma-
cokinetic change (i.e., about a 30% change
in AUC) with a power of 80% and a sig-
nificance level of P < 0.05. Our total of
44 healthy volunteers and 13 patients with
chronic end-stage liver disease were suffi-
cient for reliable data in our studies.
To minimize interindividual variation
and number of subjects needed, a cross-
over design was chosen for Studies I to IV.
Balanced randomization and adequate
washout periods (2–6 weeks) minimized
the risk of possible carry-over effects. As
the menstrual cycle has no clinically sig-
nificant effect on drug elimination (Kashu-
ba and Nafziger 1998), it was considered
unnecessary to have the wash-out period
equal the average menstrual cycle of 4
weeks.
Genetic variability affects CYP-medi-
ated drug metabolism, with CYP2D6,
CYP2C9, and CYP2C19 polymorphisms
especially important clinically (Lin and Lu
1998, Scordo et al. 2002). Genetic varia-
tion in the CYP3A enzymes may also con-
tribute to overall variability in the metab-
olism of CYP3A substrates (Lamba et al.
2002). Country of residence and ethnic
origin can, to some extent, also influence
CYP1A2 (Tantcheva-Poor et al. 1999) and
CYP3A4 (Yu et al. 2001) activity. All sub-
jects in this work were Finnish residents
and of Caucasian origin. Furthermore, the
healthy volunteers in Studies I to IV served
as their own controls to minimize interin-
dividual variability, and no CYP genotyp-
ing of the subjects was considered neces-
sary.
Age seems to have an effect on CYP-
mediated drug metabolism (Kinirons and
Crome 1997, Tanaka 1998). Because the
patients with liver disease in Study V were
somewhat older than the healthy controls,
some effect of age cannot be entirely ruled
out. Differences in CYP content and ac-
tivity seem, however, to be relatively small
(up to ± 16% of the level during the third
decade) among young adults and the eld-
erly (age-range 20 to 70 years) (Shimada
et al. 1994, Sotaniemi et al. 1997). In any
49
Discussion
event, any extrapolation of the present re-
sults to children or elderly subjects should
be made with caution.
The effect of oral contraceptive steroids
on the pharmacokinetics of ropivacaine,
found in the combined analysis of Studies
I to IV, was unknown at the time the indi-
vidual studies were performed. Half the
healthy volunteers serving as controls in
Study V were taking oral contraceptive ste-
roids and probably had a lower ropivacaine
CL and higher plasma ropivacaine concen-
trations than did subjects not taking them.
Thus, had the study been done with no
control subjects on oral contraceptive ste-
roids, the differences observed in ropiv-
acaine pharmacokinetics between the con-
trols and the patients with liver disease
would probably have been even greater. On
the other hand, that some of the patients
with liver disease were taking medicines
that may reduce ropivacaine metabolism
may have partially counteracted the effect
of oral contraceptive steroid use in the
control group. In Study III, an unequal
number of smokers and nonsmokers were
on a regimen of oral contraceptive steroids,
confounding the comparison between
smokers and nonsmokers.
Clinically important drugs at typical
dosages served as inhibitors and inducers
in Studies I to IV. The doses and lengths
of the pretreatment periods were similar
to the ones previously involved in clini-
cally significant drug-drug interactions.
Our purpose was to investigate the phar-
macokinetics of ropivacaine. For this rea-
son and for ethical reasons, the ropivacaine
dose (0.6 mg/kg weight in all studies) was
low. Since the pharmacokinetics of clini-
cally relevant doses of ropivacaine are lin-
ear (Erichsen et al. 1996, Irestedt et al.
1997, Sandler et al. 1998), and the assay
methods applied were sensitive and spe-
cific, the results of these studies are likely
to be valid also at the higher concentra-
tions usual in clinical work.
Our sampling times proved to be ade-
quate in most cases to calculate the phar-
macokinetic variables for ropivacaine.
Venous plasma samples were collected for
up to 12 hours from the healthy volun-
teers, and up to 22 hours from the patients
with chronic end-stage liver disease. This
was judged to be relevant, considering that
in the earlier studies the ropivacaine elim-
ination t
½
 was less than 2 hours after an
intravenous infusion (Appendix 1). As the
patients with liver disease turned out to
have a mean t
½
 of 11 hours, however, a
collection period longer than 22 hours
would have been more appropriate.  More-
over, accuracy in estimating ropivacaine t
½
(about 7 hours), AUC, and CL after flu-
voxamine pretreatment in the healthy vol-
unteers in Study II could have been im-
proved with a collection period longer than
12 h. For the PPX-metabolite, the declin-
ing portion of the plasma concentration-
time curve was in many cases not reached,
and thus, determination of its elimination
t
½
 was, in these subjects, impossible.
After intravenous administration, arte-
rial plasma concentrations increase faster
than venous concentrations, and an equi-
librium is reached within 20 min (Knud-
sen et al. 1997). Peripheral venous con-
centrations depend on the perfusion of the
region the vessel is draining, and tend to
peak later than the arterial (or brain) con-
centrations (Tucker 1986). Peripheral
venous sampling was used for ethical rea-
sons. In Studies I to IV, the first plasma
sample following the end of the ropiv-
acaine infusion was taken at 15 minutes.
The actual C
max
 probably occurred some
time after the end of the infusion, and was
thus missed by a small amount. This is,
50
Discussion
however, unlikely to affect the calculated
AUC values very much.
In all studies, urine was collected for
24 h. Only 31% to 41% of the infused
ropivacaine in the healthy volunteers in the
placebo phases of Studies II to IV and in
Study V was excreted in urine within 24
hours after the start of  infusion, in the
form of unchanged ropivacaine, PPX, or
3-OH-ropivacaine (f
e
 + f
m,PPX
 + f
m,3-OH
).
This is in agreement with another interac-
tion study (Arlander et al. 1998), in which
41% of the infused dose was excreted with-
in 24 hours. Similarly, according to Hall-
din et al. (1996), after an intravenous in-
fusion of 50 mg radioactive
[14C]ropivacaine in healthy volunteers,
86% of the total radioactivity was excret-
ed in urine and 8% in feces within 96
hours. In that study in the urine, 43% of
the original dose was identified as repre-
senting: 3-OH-ropivacaine (37%), PPX
(3%), 3-OH-PPX (2%), ropivacaine (1%),
and 4-OH-ropivacaine (0.4%). The ma-
jority (80%) of the dose was excreted in
urine within 24 hours.
It is also interesting that in our patients
with end-stage liver disease and in our
healthy volunteers after rifampicin pre-
treatment only 17% to 18% of the infused
dose was excreted in urine in 24 hours.
The decreased CL of ropivacaine and ac-
cumulation of the metabolites in plasma
could explain this decreased excretion in
the patients with liver disease. However,
the rifampicin pretreatment raised the rop-
ivacaine CL, and still the excreted fraction
was lower than in the placebo phase. This
might result from an increase in the pro-
duction of metabolites other than 3-OH-
ropivacaine and PPX, or by rifampicin
inducing further metabolism of the ropi-
vacaine metabolites.
In human liver microsomes in vitro,
PPX has been the major metabolite of rop-
ivacaine (Oda et al. 1995). However, in
vivo, in Studies I to V and also in the liter-
ature (Halldin et al. 1996, Arlander et al.
1998), the major metabolite is 3-OH-rop-
ivacaine. One explanation for this discrep-
ancy may be that, at the lower concentra-
tions of ropivacaine in vivo, ropivacaine
binds to a high affinity site on the enzyme,
which then produces 3-OH-ropivacaine
(Ekstrom and Gunnarsson 1996, Halldin
et al. 1996).
Effect of inhibition and
induction of CYP1A2 and
CYP3A4 on ropivacaine
pharmacokinetics
Effect of CYP1A2 inhibitors
Fluvoxamine (100 mg once daily for 5
days) reduced ropivacaine CL by 77%, and
ciprofloxacin by 31%. Fluvoxamine also
prolonged the ropivacaine t
1/2 
from 2.3 to
7.4 hours. These results are in good agree-
ment with those of another study (Arland-
er et al. 1998), where fluvoxamine (25 mg
twice daily for 2 days) reduced ropivacaine
CL by 68% and almost doubled its elim-
ination t
½
. During continuous infusion,
at steady state, a 77% reduction in CL
would result in about a 4-fold free plasma
concentration of ropivacaine, and a 31%
reduction in CL would result in an about
a 45% increase in ropivacaine plasma con-
centration.
The mean free plasma concentration of
ropivacaine associated with CNS symp-
toms in healthy volunteers has been about
0.6 mg/L, and the lowest individual toxic
concentration about 0.3 mg/L (Knudsen
et al. 1997). A 72-h epidural infusion of
ropivacaine 20 to 30 mg/h has produced
average steady state concentrations of free
venous plasma ropivacaine of approxi-
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mately 0.06 to 0.07 mg/L postoperatively
in patients who have undergone orthope-
dic surgery (Burm et al. 2000). However,
in one of these patients, the free ropiv-
acaine concentration rose to 0.2 mg/L at
the end of the infusion. Thus, patients re-
ceiving fluvoxamine, ciprofloxacin, or
some other potent CYP1A2 inhibitor may
be at increased risk for ropivacaine toxici-
ty during a continuous infusion or during
repeated injections.
In Studies II and IV, both fluvoxamine
and ciprofloxacin caused an increase in the
excretion of ropivacaine in urine (NS for
ciprofloxacin) and in the excretion of PPX,
and they reduced the excretion of 3-OH-
ropivacaine. With both drugs the plasma
concentrations (AUC) of PPX were also
higher. In rats, the threshold for CNS tox-
icity from the plasma concentration of
unbound PPX is about one-twelfth that
from unbound ropivacaine (Ekatodramis
et al. 2003). The unbound fraction of PPX
has been reported as between 59% and
89% (Burm et al. 2000, Ekatodramis et
al. 2003), considerably higher than that
of ropivacaine. Thus, during a continu-
ous infusion to patients on a regimen of a
CYP1A2-inhibiting drug, the accumula-
tion of PPX may further increase the tox-
icity caused by higher ropivacaine plasma
concentrations.
Effect of CYP3A4 inhibitors
Itraconazole, clarithromycin, and erythro-
mycin, given alone, had no significant ef-
fect on ropivacaine CL (causing a 13%,
5%, and 10% reduction in CL). This was
also the case with ketoconazole (a 15%
reduction in ropivacaine CL) (Arlander et
al. 1998). It is not very likely, therefore,
that inhibiting CYP3A4 alone would have
a clinically significant effect on the phar-
macokinetics of ropivacaine. However, the
interaction of clarithromycin with ropiv-
acaine was concentration-dependent, and
the impact of clarithromycin may be great-
er if larger doses are used. There is also
considerable interindividual variability in
the pharmacokinetics of ropivacaine, and
the largest individual reduction in the rop-
ivacaine CL by itraconazole was 35%.
Itraconazole, clarithromycin, and eryth-
romycin all reduced the excretion of PPX
in urine
 
(NS for clarithromycin and eryth-
romycin), and erythromycin  elevated the
excretion of 3-OH-ropivacaine
 
(which was
not measured after itraconazole and
clarithromycin pretreatments). However,
3-OH-ropivacaine is significantly less toxic
than ropivacaine (Arlander et al. 1998),
and the plasma concentrations of 3-OH-
ropivacaine were not increased, so these
changes in urinary excretion are unlikely
to be of any clinical significance.
Effect of combined use of CYP1A2
and CYP3A4 inhibitors
A combined use of both  fluvoxamine and
erythromycin reduced ropivacaine CL by
86%, implying 7-fold plasma concentra-
tions of ropivacaine at steady state during
continuous infusion of ropivacaine.
Effect of rifampicin
Rifampicin clearly accelerated the elimi-
nation of ropivacaine (CL increased by
93% in nonsmokers), led to an increase
in the AUC and urinary excretion of PPX,
and reduced the AUC and excretion of 3-
OH-ropivacaine. These results are in har-
mony with the fact that rifampicin is a
potent inducer of CYP3A4 (Strayhorn et
al. 1997), the enzyme involved in the for-
mation of PPX. Rifampicin is also an in-
ducer of CYP1A2, but in Study III,
rifampicin reduced the AUC and excre-
tion of 3-OH-ropivacaine, suggesting that
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CYP3A4 was induced more than was
CYP1A2.
After rifampicin pretreatment, only
17% to 18% of the infused dose was ex-
creted in urine as ropivacaine, 3-OH-rop-
ivacaine, or PPX in 24 hours, compared
with the 35% to 41% excreted in the pla-
cebo phase. This might be explained by
an increase in the production of metabo-
lites other than 3-OH-ropivcaine and
PPX, or by rifampicin-induced further
metabolism of the ropivacaine metabolites.
Effect of smoking
The plasma and urine samples in Studies
I to IV were collected and analyzed in the
same manner, and analysis of variance was
used to determine the contribution of
study, sex, contraceptive steroid use, and
smoking to overall variance in the placebo
phases of these studies.
Of the 38 volunteers in Studies I to IV,
12 smoked cigarettes. Smoking enhances
the activity of CYP1A2 (Landi et al. 1999,
Tantcheva-Poor et al. 1999, Zevin and
Benowitz 1999). In Study III, moderate
smokers (median 13 cigarettes per day,
range 10–20) had a 19% higher ropiv-
acaine CL (NS) and excreted 31% more
3-OH-ropivacaine in urine than did the
nonsmokers (P < 0.05). In Studies I to IV,
those smoking a median 5 (range “irregu-
larly” to 20) cigarettes per day had a 5%
higher ropivacaine CL (NS) and excreted
17% more 3-OH-ropivacaine than did
nonsmokers (NS; Table 3, Fig. 2), in ac-
cordance with the report indicating that
smoking increases CYP1A2 activity in a
dose-dependent manner (Tantcheva-Poor
et al. 1999).
The small effect of smoking on the
pharmacokinetics of the CYP1A2 sub-
strate ropivacaine is somewhat surprising,
considering that 3-OH-ropivacaine is the
major CYP-dependent metabolite of rop-
ivacaine, and that smoking 11 to 20 ciga-
rettes per day has been associated with a
1.7-fold increase in CYP1A2 activity
(Tantcheva-Poor et al. 1999). This discrep-
ancy may be partly related to the con-
founding effect of oral contraceptive ste-
roids, as discussed in the first part of this
Discussion.
For some reason, the smokers in Stud-
ies I to IV had a 143% higher f
e
 than non-
smokers. A possible explanation is in-
creased cardiac output in smokers, since
smoking causes resting heart rate and con-
tractility to rise (Behr et al. 1981). Anoth-
er explanation may be a differing urine pH
between smokers and nonsmokers having
an influence on ropivacaine excretion
(Rowland and Tozer 1995). However, this
difference in f
e
 did not appear in Study
III.
Effect of chronic end-stage
liver disease
Compared with healthy volunteers, pa-
tients with chronic end-stage liver disease
had about a 60% lower mean CL of both
total and free ropivacaine. Further, the
patients had a somewhat larger V
ss
 and a
slightly lower C
max
. Thus, the increased risk
for ropivacaine toxicity in patients with
chronic end-stage liver disease seems to be
associated with continuous infusions
(where one can expect plasma concentra-
tions at steady state to be about 2.5-fold
those in healthy subjects), rather than with
a single administration of ropivacaine.
However, what cannot be excluded is that,
even after a single dose of ropivacaine,
three variables: 1) absorption of ropiv-
acaine from the site of injection, 2) phar-
macodynamic effects of ropivacaine, or 3)
hemodynamic effects of implementing re-
gional anesthesia per se may differ between
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patients with end-stage liver disease and
healthy subjects.
Patients in Study V were evaluated  for
liver transplantation at the time they par-
ticipated in the study, and all had severe
chronic end-stage liver disease. It is rea-
sonable to believe that ropivacaine CL is
less affected in patients with less severe liver
disease.
The patients had a higher f
e
 (2.1% vs.
0.3%) and a lower f
m,3-OH
 (11% vs. 27%)
than did healthy volunteers. No signifi-
cant difference appeared in the f
m,PPX
 (4.7%
vs. 5.0%). In the patients, only 18% of
the infused dose was excreted in urine as
ropivacaine, 3-OH-ropivacaine, or PPX in
24 hours, compared with 32% in the
healthy volunteers. This is probably ex-
plained by patients’ diminished ropiv-
acaine metabolism, so that a larger pro-
portion of the ropivacaine had not been
metabolized in 24 hours, compared with
that in the healthy volunteers.
One of the patients had ventricular ex-
trasystoles during the ropivacaine infusion,
and another patient experienced a tingling
feeling in her tongue 1 to 2 hours after the
start of the infusion. The free venous plas-
ma concentrations of ropivacaine in these
patients at the end of infusion were 0.02
mg/L and 0.03 mg/L—concentrations
probably too low to be responsible for the
adverse events, especially since the symp-
toms did not commence at the time of the
C
max
. Healthy volunteers tolerated a mean
0.56 mg/L (minimum 0.34 mg/L) arteri-
al free plasma concentration during an
intravenous 10 mg/min infusion of ropi-
vacaine (Knudsen et al. 1997). Generally,
free arterial plasma concentrations (rather
than free venous concentrations of a mean
0.15 mg/L and minimum 0.01 mg/L), are
related to local anesthetic toxicity during
a rapid input of the drug, when there exist
an arterio-venous concentration differ-
ence. After intravenous administration,
arterial plasma concentrations increase
faster than the venous, and equilibrium is
reached within 20 min after the infusion
ends (Knudsen et al. 1997). In Study V,
the mean ropivacaine infusion rate was
considerably lower (about 1.3 mg/min)
than in the study by Knudsen et al. (1997),
and we used peripheral venous sampling.
Effect of gender
Women are often reported to have a high-
er hepatic CYP3A activity than that of men
(Hunt et al. 1992, Harris et al. 1995, Gle-
iter and Gundert-Remy 1996, Tanaka
1999, Rademaker 2001), and men have
the higher CYP1A2 activity (Landi et al.
1999, Meibohm et al. 2002, Rasmussen
et al. 2002). Although the present studies
were not balanced with respect to subjects’
gender, in Studies I to IV no differences
appeared in the f
m,PPX
 and f
m,3-OH
 between
men and women (those not on contracep-
tive steroids) (Table 4, Fig. 6). Further-
more, the healthy volunteers in these stud-
ies served as their own controls.
Effect of oral contraceptive
steroids
Of the 22 women in Studies I to IV, 13
were on a regimen of oral contraceptive
steroids, and one had a subcutaneous
levonorgestrel implant (Table 4, Fig. 3).
Palovaara et al. (2000) have  reported a
modest reduction in the activity of
CYP3A4 caused by a combined oral con-
traceptive preparation (30 µg ethinylestra-
diol and 75 µg gestodene). After treatment
with an oral contraceptive formulation
containing 75 µg gestodene and 30 µg ethi-
nylestradiol, the CL of caffeine, metabo-
lized mostly by CYP1A2, was reduced by
54%, and after treatment with a formula-
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tion containing 125 µg levonorgestrel and
30 µg ethinylestradiol, by 55% (Balogh et
al. 1995). CYP1A2-mediated 1’-hydrox-
ylation of tacrine was reduced by about
30% by concomitant hormone replace-
ment therapy (Laine et al. 1999). In Stud-
ies I to IV, the subjects on oral contracep-
tive steroids demonstrated a decreased rop-
ivacaine CL (by 49%), a lower f
m,3-OH
, and
a higher f
m,PPX
, than did subjects not using
contraceptive steroids. This suggests inhi-
bition of CYP1A2-mediated formation of
3-OH-ropivacaine by oral contraceptive
steroids.
Of the 17 subjects in Studies II and IV,
7 were on a regimen of oral contraceptive
steroids. This may have diminished the
CYP1A2-inhibiting effect of fluvoxamine
and ciprofloxacin, since CYP1A2 in sub-
jects using oral contraceptives may already
have been partly inhibited in the placebo
phases.
Effect of Study
In statistical analysis of Studies I to IV,
ropivacaine AUC was significantly higher
in the placebo phase of Study IV than of
Study III (2.2 vs. 1.5 mg · L-1 · h). This
may be explained by the fact that more
smokers (44% vs. 0%) and fewer oral con-
traceptive users (28% vs. 44%) were in-
cluded in Study III than in Study IV.
Ropivacaine
pharmacodynamics and
absorption-related
considerations
In the present studies, a small dose of
ropivacaine was given intravenously, with-
out any intention to study the pharmaco-
dynamic effects or absorption of ropiv-
acaine. These issues are, however, also im-
portant in clinical work.
Duration of a neural blockade depends
on absorption of the local anesthetic from
the site of administration (Emanuelsson
et al. 1997a, Thomas and Schug 1999).
Absorption of local anesthetics is primari-
ly and directly related to local blood flow
and inversely related to local tissue bind-
ing (Tucker 1986). The rate of dissocia-
tion of local anesthetics from proteins and
adipose tissue at the injection site depends
on drug-specific factors such as degree of
ionization, lipophilicity, and plasma-pro-
tein binding (Thomas and Schug 1999).
In the present studies, a small dose of rop-
ivacaine was given intravenously, and thus
no absorption-data or clinically relevant
pharmacodynamic data were available.
From a theoretical point of view, it does
not seem plausible that fluvoxamine,
ciprofloxacin, itraconazole, clarithromy-
cin, erythromycin, or rifampicin would
have a clinically significant effect on the
absorption or on the pharmacodynamics
of local anesthetics. Thus, it is not likely
that these drugs would influence the du-
ration or intensity of the neuronal block
produced by ropivacaine, even if some of
them affected the elimination of ropiv-
acaine. With cigarette smoking, pharma-
codynamic interactions with benzodiaz-
epines, beta-blockers, and opioids have
been described (Zevin and Benowitz
1999), but no pharmacodynamic interac-
tions with a local anesthetic have been re-
ported. Smoking increases resting heart
rate and contractility (Behr et al. 1981),
and thus theoretically may increase the
absorption of local anesthetics. On the
other hand, nicotine is a vasoconstrictor,
which may have the opposite effect on
blood flow at the site of local anesthetic
injection. The effect of smoking on ropiv-
acaine absorption is unlikely to be clini-
cally relevant.
To the best of our knowledge, no data
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is available on the effect of chronic end-
stage liver disease on the absorption or
pharmacodynamics of local anesthetics.
Patients with liver cirrhosis have an in-
creased cardiac output (Moller and Hen-
riksen 2002), but no recent data seem to
show whether this affects absorption of
local anesthetics.
In the peripheral neuropathy often as-
sociated with end-stage liver disease, sen-
sory and motor nerve conduction is im-
proved after liver transplantation (Höck-
erstedt et al. 1992, Lee et al. 2002). Thus,
end-stage liver disease seems to affect nerve
impulse conduction, and one cannot rule
out a possible pharmacodynamic interac-
tion between chronic end-stage liver dis-
ease and local anesthetics.
In uremic patients (Pere et al. 2003),
absorption or ropivacaine after an axillary
plexus block seemed to be similar to the
absorption in nonuremic patients (based
on the similar C
max
, t
max
, and t
½ 
of free rop-
ivacaine). Increased plasma AAG levels
raised plasma concentrations and reduced
ropivacaine CL in uremic patients, whereas
the CL values of the unbound drug in both
groups were similar. Based on animal data
(Brismar and Tegner 1984) and a case re-
port on tetrodotoxin intoxication (Lan et
al. 1999), uremia seems to reduce sodium
permeability and depolarization of excita-
tory membranes, and thus might aggra-
vate  the sodium-channel blocking effect
of local anesthetics.
Toxicity
The systemic toxicity of local anesthetics
is related to the free plasma concentrations
of the drug (Tucker 1986), and thus de-
pends on both the absorption and the dis-
position of the drug (Emanuelsson et al.
1997a).
As already mentioned, the CYP inhib-
itors and inducers studied here are unlike-
ly to affect ropivacaine absorption. Chang-
es in ropivacaine disposition will then like-
ly be the main pharmacokinetic alterations
caused by these CYP-modulating drugs.
The C
max
 after a single injection depends
on the dose used, on absorption of the drug
from the site of injection, and on disposi-
tion (elimination and distribution) of the
drug from the plasma. It is reasonable to
expect that the decrease in ropivacaine CL
due to CYP1A2 inhibitors or liver disease
is not going to have a major impact on
ropivacaine C
max
 after a single dose. Even
when ropivacaine is administered region-
ally (extravascularly), its absorption is usu-
ally relatively fast compared with its elim-
ination—the t
½
 of the fast phase of ropiv-
acaine absorption from epidural space is
14 min (Emanuelsson et al. 1997a)—
which reduces the effect of elimination on
the C
max
.
If the absorption of ropivacaine is un-
changed in liver disease, the situation is
about the same as with the CYP1A2 in-
hibitors, and the ropivacaine C
max
 after a
single injection is probably not consider-
ably higher. One has to keep in mind,
however, the possible changes occurring
in pharmacodynamics in liver disease (and
in uremia).
A reduction in V
ss
 would lead to an in-
creased C
max
, but the V
ss
 of ropivacaine was
neither lower in liver disease nor reduced
by any of the drug interactions studied.
The main risk from a decreased ropiv-
acaine CL is associated with the use of
continuous infusions or multiple injec-
tions. Toxic symptoms from local anesthet-
ics are related to the free plasma concen-
trations of local anesthetics. Because the
hepatic extraction rate of ropivacaine is
relatively low (about 40%), its free plasma
concentration is inversely related to the
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unbound CL during continuous admin-
istration (i.e., a 50% decrease in unbound
CL results in a 2-fold free drug concentra-
tion in plasma).
Because ropivacaine is metabolized by
CYP1A2 and CYP3A4, it was expected
that drugs known to inhibit these enzymes,
and  that end-stage liver disease, as well,
would reduce ropivacaine CL. This proved
to be true for CYP1A2 inhibitors, for com-
bined use of CYP1A2 and CYP3A4 in-
hibitors, and for end-stage liver disease.
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Clinical implications
Inhibitors of CYP1A2 and CYP3A4 are
unlikely to affect the safety of a single in-
jection of ropivacaine. Clinicians should,
however, be aware of increased plasma con-
centrations of ropivacaine in patients re-
ceiving potent CYP1A2 inhibitors and in
patients with chronic end-stage liver dis-
ease receiving a continuous infusion or
multiple injections of ropivacaine. Dur-
ing such a continuous ropivacaine infu-
sion, concomitant use of potent inhibitors
of both CYP1A2 and CYP3A4 can result
in about a 7-fold plasma ropivacaine con-
centration.
Conclusions
1. Fluvoxamine and ciprofloxacin reduce
ropivacaine clearance (by about 80%
and about 30%), reduce production of
3-OH-ropivacaine, and raise produc-
tion of PPX.
2. Itraconazole, clarithromycin, and eryth-
romycin each has only a minor effect
on ropivacaine clearance.
3. Combined use of fluvoxamine and
erythromycin reduces ropivacaine clear-
ance (by about 90%).
4. Oral contraceptives reduce ropivacaine
clearance (by about 50%).
5. Cigarette smoking, known to induce
biotransformation of drugs metabolized
by CYP1A2, has only a minor effect on
ropivacaine clearance, but leads to in-
creased production of 3-OH-ropiv-
acaine and reduces PPX production.
6. Rifampicin, a potent inducer of
CYP3A4 and of some other CYP en-
zymes, enhances ropivacaine clearance
(by about 90%), raises production of
PPX, and reduces production of 3-OH-
ropivacaine.
7. Chronic end-stage liver disease reduces
ropivacaine clearance (by about 60%).
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